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STREPTAVIDIN-BINDING PEPTIDES AND 
USES THEREOF 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
embodiment, the dissociation constant is less than 10 pM, 5 
pM, 1 pM, 100 nM, 50 nM, or 25 nM; and greater than 0.01 
nM, 0.1 nM, 1 nM, 5 nM, or 10 nM. In another preferred 
embodiment, the value of the dissociation constant is con- 
s tained in one of the following ranges: 5 pM to 1 pM, 1 pM 
to 100 nM, 100 nM to 50 nM, 50 nM to 25 nM, 25 nM to 
10 nM, 10 nM to 5 nM, 5 nM to 1 nM, or 5 nM to 0.1 nM, 
inclusive. 
In another related aspect, the invention provides a peptide 
10 which binds streptavidin with a dissociation constant less 
than 23 nM, 10 nM, or 5 nM. In one preferred embodiment, 
the peptide is disulfide bonded or cyclized. In another 
This invent ion was funded  by g r a n t  number preferred embodiment, the dissociation constant is less than 
ROlGM53936 from the National Institutes of Health and 23 nM, nM, or 5 nM; and greater than o,ol nM, o,l nM, 
grant number NCC-2-1069 from NASA. The government 15 or 1 nM. In another preferred embodiment, the value of the 
dissociation constant is contained in one of the following may have certain rights in the invention. 
This application claims benefit from U.S. Provisional 
application Ser. No. 601244,541, filed Oct. 31,2000, hereby 
incorporated by reference. 
STATEMENT AS TO FEDERALLY SPONSORED 
RESEARCH 
BACKGROUND OF THE INVENTION ranges: 20 nM to 10 nM, 10 nM to 5 nM, 5 nM to 1 nM, or 5 nM to 0.1 nM, inclusive. 
In general, the invention features novel compounds and 
methods for purifying or detecting proteins of interest. 
Determining the enzymatic activity, binding specificity, or 
three-dimensional structure of a protein often requires the 
purification of the protein from a complex mixture of other 
components, such as compounds present in a cell lysate or 
In other related aspects, the invention provides nucleic 
20 acids encoding the peptides of the present invention, and 
In addition, standard gene fusion techniques may be used 
vectors that include such nucleic acids. 
to generate fusion nucleic acids that encode fusion proteins 
which include a peptide of the present invention and a 
in vitro translation extract. With the number of known 25 protein of interest. The fusion proteins may be purified, 
proteins increasing dramatically as a result of whole genome detected, or quantified based on the high affinity of the 
sequencing projects, it has become crucial to find alterna- peptides for streptavidin. 
tives to traditional, time-consuming monoclonal antibody Accordingly, in one such aspect, the invention provides a 
production for generating affinity reagents for the detection fusion protein including a protein of interest covalently 
and purification of proteins. In addition, purifying a novel 30 linked to one of the following peptides: a peptide which 
Protein using traditional column chromatography methods binds streptavidin with a dissociation constant less than 10 
often requires much trial and error to develop a purification p~ and which is not disulfide bonded or cyclized, (b) a 
Protocol that results in the recovery of the Protein in high peptide which binds streptavidin with a dissociation constant 
yield and purity. 35 less than 10 pM and which does not contain an HPQ, HPM, 
Thus, purification methods are needed that may be gen- HPN, or HQP motif, or (c) a peptide which binds strepta- 
erally applied to proteins of interest, that utilize inexpensive vidin with a dissociation constant less than 23 nM. In 
reagents, and that result in highly purified protein without preferred embodiments, the peptide is attached to the amino- 
requiring multiple chromatography steps. terminus or the carboxy-terminus of the protein of interest, 
4o or the peptide is positioned between the amino and carboxy- 
termini of the protein of interest. Preferably, the peptide is SUMMARY OF THE INVENTION 
The purpose of the present invention is to provide linked to the protein of interest by a linker which includes a 
improved reagents for the purification, detection, or quan- protease-sensitive site. 
titation of proteins of interest. In particular, the high affinity, In related aspects, the invention provides nucleic acids 
streptavidin-binding peptides of the present invention may 45 encoding the fusion proteins of the present invention, and 
be used as affinity tags for the purification of fusion proteins vectors that include these fusion nucleic acids. 
containing proteins of interest. In addition, the invention provides a method of producing 
Accordingly, in a first aspect, the invention provides a a fusion protein of the present invention. This method 
peptide which binds streptavidin with a dissociation constant includes transfecting a vector having a nucleic acid sequence 
less than 10 pM (that is, binds streptavidin more tightly than 50 encoding the fusion protein into a suitable host cell and 
a KD of 10 pM) and which is not disulfide bonded or culturing the host cell under conditions appropriate for 
cyclized. Preferably, the dissociation constant is equal to or expression of the fusion protein. 
less than 5 PM, 1 PM, 100 nM, 50 nM, 25 nM, 10 nM, Or The fusion proteins described herein may be used in 
even 5 nM. In one preferred embodiment, the dissociation methods for purifying proteins of interest from samples, 
constant is less than 10 iuM, 5 iuM, 1 PM, 100 nM, 50 nM, ss Such a method involves expressing the protein of interest as 
or 25 nM; and greater than 0.01 nM, 0.1 nM, 1 nM, 5 nM, a fusion protein covalently linked to one of the following 
or 10 nM. In another preferred embodiment, the value of the peptides: (a) a peptide which binds streptavidin with a 
dissociation constant is contained in one of the following dissociation constant less than 10 pM and which is not 
ranges: 5 iuM to 1 iuM, 1 iuM to 100 nM, 100 nM to 50 nM, disulfide bonded or cyclized, (b) a peptide which binds 
50 nM to 25 nM, 25 nM to 10 nM, 10 nM to 5 nM, 5 nM 60 streptavidin with a dissociation constant less than 10pM and 
to 1 nM, or 5 nM to 0.1 nM, inclusive. which does not contain an HPQ, HPM, HPN, or HQP motif, 
In a related aspect, the invention provides a peptide which or (c) a peptide which binds streptavidin with a dissociation 
binds streptavidin with a dissociation constant less than 10 constant less than 23 nM. A sample containing the fusion 
pM. The amino acid sequence of the peptide does not protein is contacted with streptavidin under conditions that 
contain an HPQ, HPM, HPN, or HQP motif. Preferably, the 65 allow complex formation between the fusion protein and 
dissociation constant is equal to or less than 5 pM, 1 pM, 100 streptavidin. The complex is isolated, and the fusion protein 
nM, 50 nM, 25 nM, 10 nM, or 5 nM. In one preferred is recovered from the complex, thereby purifying the protein 
US 6,841,359 B2 
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of interest from the sample. In one preferred embodiment, 
the protein of interest is recovered from the fusion protein by 
cleaving the streptavidin-binding peptide from the fusion 
protein. 
In yet another aspect, the invention provides a method of 
detecting the presence of a fusion protein of the present 
invention in a sample. This method includes (a) contacting 
the sample with streptavidin or a streptavidin-containing 
compound under conditions that allow complex formation 
between the fusion protein and either streptavidin or the 
streptavidin-containing compound; (b) isolating the 
complex, and (c) detecting the presence of streptavidin or 
the streptavidin-containing compound in the complex or 
following recovery from the complex. The presence of 
streptavidin or the streptavidin-containing compound indi- 
cates the presence of the fusion protein in the sample. 
Preferably, step (c) also involves measuring the amount of 
streptavidin or the streptavidin-containing compound in the 
complex or following recovery from the complex. The 
amount of fusion protein in the sample is correlated with, 
and may be calculated from, the measured amount of 
streptavidin. For example, for a fusion protein containing a 
peptide that binds one molecule of streptavidin per molecule 
of peptide, the amount of fusion protein in the sample is 
predicted to be approximately the same as the amount of 
streptavidin measured. In one preferred embodiment, the 
amount of streptavidin is determined using Western or 
ELISA analysis with an antibody that reacts with streptavi- 
din or that reacts with a compound that is covalently linked 
to streptavidin. In another preferred embodiment, streptavi- 
din is covalently linked to an enzyme, radiolabel, fluorescent 
label, or other detectable group, and the amount of strepta- 
vidin is determined using standard techniques based on a 
characteristic of the detectable group such as its enzyme 
activity, radioactivity, or fluorescence. 
In another aspect, the invention features a method of 
determining the affinity of a compound of interest for a 
target molecule. The method includes incubating a solution 
having a compound of interest with a detectable group and 
a free target molecule under conditions that allow complex 
formation between the compound of interest and the free 
target molecule. The solution is contacted with a target 
molecule immobilized on a solid support under conditions 
that allow complex formation between the compound of 
interest and the immobilized target molecule, and the com- 
pound of interest bound to the immobilized target molecule 
is then separated from the compound of interest not bound 
to the immobilized target molecule. To determine the 
affinity, either the amount of the compound of interest that 
is bound to the immobilized target or the amount of the 
compound of interest not bound to the target molecule is 
then measured. In yet another preferred embodiment, the 
steps of this method are repeated one or more times with a 
different concentration of free target molecule. In other 
preferred embodiments, both the amount of the compound 
of interest bound to the immobilized target molecule and the 
amount of the compound of interest not bound to the 
immobilized target molecule are measured. In another 
embodiment, only the amount of the compound of interest 
that is not bound to the immobilized target molecule is 
measured. In another embodiment, the target is immobilized 
on a solid support such as a microtiter plate, a bead, or the 
matrix of a spin-filter column. In another embodiment, the 
compound of interest that is bound to the immobilized target 
molecule is separated from the compound of interest that is 
not bound to the immobilized target molecule by 
centrifugation, for example, by spin-filtration or ultracen- 
trifugation. In still other preferred embodiments, the target is 
a small molecule such as streptavidin, a streptavidin fusion 
protein, streptavidin covalently bound to an enzyme (e.g. 
horseradish peroxidase or alkaline phosphatase), or a ligand. 
5 The compound of interest may be a peptide that binds 
streptavidin, or may be a fusion protein that includes a 
peptide that binds streptavidin and a protein of interest. In 
other embodiments, the compound of interest may be 
labeled with a detectable group, such as a radiolabel, a 
fluorescent molecule, or an enzyme. 
In preferred embodiments of various aspects of the 
invention, the amino acid sequence of the peptide includes 
at least 10, 25, 50, 75, or 100 consecutive amino acids or 
consists of between 5 and 150,lO and 100,20 and 75, or 30 
and 50 amino acids, inclusive, of any one of SEQ ID Nos. 
1-29 or 35. Preferably, the amino acid sequence of the 
peptides includes an LPQ, QPQ, EPQ, HPA, HPD, or HPL 
motif. In other preferred embodiments, the amino acid 
sequence includes any one of SEQ ID Nos. 1-29 or 35. In 
still other preferred embodiments, the peptide has an amino 
2o acid sequence that is at least 20, 30, 40, 50, 60, 70, 80, 90, 
95, or 100% identical to any one of SEQ ID Nos. 1-29 or 35. 
It is also contemplated that the affinity of the peptides of 
the present invention for streptavidin may be increased by 
incorporating disulfide bonds into, or cyclizing, the peptides. 
By constraining the peptides, the amount of disorder inher- 
ent in the peptides (i.e., entropy) decreases, and thus binding 
of these peptides to streptavidin may require less energy. It 
is also contemplated that the three-dimensional structure of 
peptides of the invention bound to streptavidin may be 
experimentally determined or modeled based on the known 
crystal structure of streptavidin and used to determine pos- 
sible modifications to the peptides that may further improve 
their affinity for streptavidin. 
As used herein, by “nucleic acid” is meant a sequence of 
two or more covalently bonded naturally-occurring or modi- 
fied deoxyribonucleotides or ribonucleotides. 
By “peptide” is meant a sequence of two or more 
covalently bonded naturally-occurring or modified amino 
4o acids. The terms “peptide” and “protein” are used inter- 
changeably herein. 
By “covalently linked” is meant covalently bonded or 
connected through a series of covalent bonds. A group that 
is covalently linked to a protein may be attached to the 
45 amino-terminus, carboxy-terminus, between the amino- and 
carboxy-termini, or to a side chain of an amino acid in the 
protein. 
By “streptavidin” is meant any streptavidin molecule or 
fragment thereof or any protein that has an amino acid 
50 sequence that is at least 80, 90, 95, or 100% identical to a 
streptavidin molecule or fragment thereof (see, for example, 
Haeuptle et al. J. Biol. Chem. 258: 305, 1983). Apreferred 
fragment of streptavidin is “core” streptavidin, which is a 
proteolytic cleavage product of streptavidin (Bayer et al. 
5s Biochem. J. 259,369-376, 1989). Preferably, a streptavidin 
molecule or fragment thereof is capable of binding biotin or 
any other streptavidin-binding molecule. Streptavidin or a 
streptavidin fragment may be modified chemically or 
through gene fusion technology or protein synthesis so that 
60 it is covalently linked to an enzyme, radiolabel, fluorescent 
label, or other detectable group. These detectable groups 
may be used to determine the presence or location of a 
streptavidin-bound fusion protein in a cell or sample or to 
quantify the amount of a streptavidin-bound fusion protein, 
By a “streptavidin-containing compound” is meant any 
compound that includes streptavidin covalently bound to 
10 
2s 
30 
3s 
65 using standard methods. 
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another molecule. These compounds may, for example, be Using the methods described herein, purification of a 
conjugated to streptavidin through gene fusion technology fusion protein based on its affinity for streptavidin has 
or protein synthesis and may, for example, be covalently allowed the isolation of the fusion protein in significantly 
linked to an enzyme, such as horseradish Peroxidase Or higher purity than that obtained using a hexahistidine affinity 
alkaline Phosphatase, a fluorescent group, a radiolabel, Or s tag or maltose-binding protein affinity tag. Moreover, 
any other detectable group. streptavidin is an inexpensive reagent that may be purchased 
BY ‘‘free target molecule” is meant a target molecule that unmodified or covalently labeled with a detectable group 
is not bound to a solid support. (such as FITC-streptavidin or alkaline phosphatase- 
BY ‘‘CYcliZe~’ is meant nonlinear. A Peptide may be conjugated streptavidin) or with a chromatography matrix 
cyclized by the formation of a COvalent bond between the IO (such as streptavidin-agarose). The availability of these 
N-terminal amino group Of the peptide Or the side-chain Of reagents simplifies methods for detecting and purifying the 
a residue and the C-terminal carboxyl group or the side- fusion proteins of the present invention, 
chain of a residue. For example, a peptide lactam may be 
group or an amino group of an amino acid side-chain and the ticularly useful when intermediate amounts of protein 
15 (-lCr500 pg) need to be produced and purified in a high C-terminal carboxyl group or a carboxyl or amide contain- 
ing side-chain, Other possible cyc~izations include the for- throughput manner. For parallel purification 
mation of a thioether by the reaction of a thiol group in a protocols may be performed in 96-we11 plates 
cysteine side-chain with the N-terminal amino group, streptavidin-derivatized magnetic beads and streptavidin 
C-terminal carboxyl group, or the side-chain of another binding peptide -tagged proteins expressed in E. 
amino acid, A disulfide bond may also be formed between 20 coupled in vitro transcriptionitranslation reactions. This 
two cysteine residues, As used herein, a ~~non-cyclized facilitates purification, for example, for proteomics applica- 
peptide,, is a linear peptide that does not have any of the tions in which thousands of purified proteins need to be 
generated and purified in parallel. above cyclizations. 
B~ “dissociation constant>> is meant the dissociation con- Other features and advantages of the invention will be 
stant for binding streptavidin as measured using the elec- 25 apparent from the following detailed description and from 
trophoretic mobility shift assay described herein. By “less 
than” a particular dissociation constant is meant capable of 
binding streptavidin more tightly than the strength of bind- 
ing represented by a particular dissociation constant. FIG. 1 A  is a schematic illustration of an in vitro selection 
B~ ((purifying>> is meant separating a compound, for process according to the invention, showing the structure of 
example, a protein, from other components that naturally the library and the scheme. Members Of the DNA 
accompany it. Typically, a protein is substantially pure when library have, from the 5’ to 3’ end, a T7 RNA Polymerase 
it is at least 50%, by weight, free from proteins and promoter (T7), a tobacco mosaic virus translation enhancer 
naturally-occurring organic molecules with which it is natu- 35 (TMV), a start codon (ATG), 88 random amino acids, a 
rally associated. Preferably, the protein is at least 75%, more hexahistidine tag (H6), and a 3’ constant region (Const). 
preferably, at least 90%, and most preferably, at least 99%, FIG. 1B is a picture of an SDS-PAGE gel of samples from 
by weight, pure. In other preferred embodiments, the protein the library at different stages of preparation. The first lane 
is at least 2,5,10,25,50, or 100 times as pure as the starting shows the result of translating the mRNA display template 
material. Purity may be assayed by any appropriate method, 40 with 35S-methionine. Most of the counts represent free 
such as polyacrylamide gel electrophoresis, column peptide (free pep), but a significant amount of mRNA- 
chromatography, optical density, HPLC analysis, western peptide covalent fusions are also present (mRNA-pep). 
analysis, or ELISA(see, for example, Ausubel et al., Current There is also another band that is independent of added 
Protocols in Molecular Biology, John Wiley & Sons, New template (NS, non-specific), and some counts remain in the 
York, 2000). 45 gel well. The band corresponding to the mRNA-peptide can 
B~ ‘‘recovered from the complex” is meant physically be shifted to a position slightly higher than that for the free 
separated from the complex of streptavidin and the fusion Peptide by the addition of RNase A. The remaining lanes 
protein. For example the streptavidin-bound fusion protein show the result of successive Oligo-dT and Ni-NTA 
may be incubated under conditions that reduce the affinity of Purifications, and finally reverse transcription 
the fusion protein for streptavidin (i.e., at low or high salt 50 FIG. 2Ais a bar graph showing the fraction of 35S counts 
concentrations or at low or high pH values) or incubated in from the displayed peptides that bound to streptavidin and 
the presence of molecules that compete with the fusion eluted with biotin, at each round of selection. FIG. 2B is a 
protein for binding streptavidin. Preferably, either the fusion graph showing the elution profile for the peptide library 
protein or the streptavidin that has been released from the generated from the output of the seventh round of selection 
complex is isolated using standard procedures, such as 5s in FIG. 2A. The first fraction represents the flow-through. 
c o l u m n  c h r o m a t o g r a p h y ,  p o l y a c r y l a m i d e  g e l  Biotin was added at the point indicated. The plot compares 
electrophoresis, HPLC, or western analysis. the binding of the intact, reverse-transcribed, displayed 
The present invention provides a number of advantages Peptides (mRNA-PeP), the Same sample treated with RNase 
related to the detection and purification of proteins of A, and the RNase-treated sample applied to a streptavidin 
require the generation of an antibody or other affinity reagent away Prior to exposing the library to the matrix). 
that is specific for each protein of interest, these methods FIG. 3 is a list of the sequences of 20 clones from the 
may be universally applied to any protein. In addition, if seventh round of selection (SEQ ID Nos.: 1-20). The “W’ 
desired, the streptavidin-binding peptide may be connected column indicates the number of times each sequence was 
to the protein of interest through a protease cleavable linker, 65 observed. The HPQ sequence is in bold type. Non-random 
allowing removal of the peptide after purification of the sequences at the termini are underlined. The six C-terminal- 
fusion protein. most residues are not shown. 
formed by the cyclization between the N-terminal amino In addition, the streptavidin binding peptide-tag are par- 
Or in 
the 
BRIEF DESCRIPTION OF THE DRAWINGS 
3o 
interest, For example, because the present methods do not 60 column pre-saturated with biotin (excess biotin was washed 
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FIG. 4A is a picturc of a native gel showing an electro- sequence of the encoded fusion protein. The sequence of the 
phoretic mobility shift (EMSA) analysis demonstrating the streptavidin-binding peptide which contains the first 38 
binding of four different DNA-tagged peptides to streptavi- amino acids of the SB19-C4 peptide is underlined. 
din. The migration of each clone is shown in the absence (-) FIG. 10.4 is a graph of the Biacore (Surface Plasmon 
and presence (+) of 1 pM streptavidin. Some of the clones 5 Resonance) response units over various lengths of time for 
show multiple bands, presumably representing different the dissociation of streptavidin from the fusion protein listed 
conformations. The arrows show the position of the gel well, in FIG. 9B immobilized on a biacore chip. For line “a,” the 
which often contains a fraction of the counts. FIG. 4B is a streptavidin concentration is 23 PM; for line “b,” the con- 
picture of a native gel showing the titration of the full-length centration is 11.5 @& and for line ‘‘c,)’ the concentration is 
clone SB19 with streptavidin. The streptavidin concentra- 10 5.75 pM. This data was used to calculate an upper limit of 
tion in each lane, from left to right, is: 3.8, 6.6, 10, 15, 23, ~ X I O - ~ / S  for the dissociation rate, KD FIG. 10B is a graph 
35, and 61 nM. FIG. 4C is a curve fit of the data shown in showing the association and subsequent dissociation of 
FIG. 4B (the fraction of peptide bound could not be accu- streptavidin from the immobilized fusion protein. For lines 
rately determined for the point with the lowest concentration “a” through “f,” the streptavidin concentrations are 1.6, 0.8, 
of streptavidin). Assuming that the peptide is homogeneous 15 0.4, 0.2, 0.1, and 0.05 pM, respectively. This data was used 
and 100% active, the data from this experiment give a KD of to calculate an association rate, k,, of 5x1O4/M/s. 
10 nM for the binding of peptide SB 19 to streptavidin. FIG. 11 is a map of the pTAG2K vector indicating the 
FIG. 5 is a list of the sequences of truncation mutants of order of the domains in the multiply-tagged fusion protein it 
peptide SB19 (SEQ ID Nos.: 21-29). The full-length (FL), encodes. 
C-terminal deleted (Cl-C4), N-terminal deleted (Nl-N3), 2o FIG, 12 is a graph showing a K~ determination of the 
and point mutated (MI) peptide sequences are shown. The streptavidin binding peptides-streptavidin interaction using 
“% binding” refers to the performance of these peptides in the Spin-filter Binding Inhibitionhsay (SBIA), ne labeled 
the streptavidin column-binding assay. streptavidin binding peptide-tagged peptide was incubated 
FIG. 6Ais the nucleotide sequence of the plasmid used for with a range of streptavidin concentrations and the amount 
expression of a fusion protein containing a streptavidin- 25 not complexed was then determined after a short incubation 
binding peptide (SEQ ID No.: 37). FIG. 6B is the amino acid with immobilized streptavidin. This analysis gave a KD of 
sequence of the encoded protein (SEQ ID No.: 38) which 2.5 nM for the interaction of the streptavidin binding peptide 
contains, from the amino- to carboxy-terminus, maltose- sequence with streptavidin. 
binding protein, a streptavidin-binding peptide (SEQ ID FIG. 13 is a purity assay for a single-step purification of 
No.: 35, FIG. 7A), a hexahistidine tag, and another peptide 30 streptavidin binding peptide-tagged (multiply-tagged) pro- 
2r18-19dN (SEQ ID No.: 39). cessed upon the basis of the His-tag or the maltose-binding 
FIG. 7A is the amino acid sequence of the streptavidin- protein sequences contained in the same protein. Lanes 1 
binding peptide (SEQ ID No.: 35) used as an affinity tag for 35 and 2 show lysed E. coli prior to and after IPTG-induction, 
the purification of the fusion protein listed in FIG. 6B. This respectively. Lane 3 shows the soluble fraction of E. coli 
peptide contains the first 38 amino acids oi the SB19-C4 lysate in streptavidin-binding buffer. Lanes 4 through 6 show 
peptide (FIG. 5).  FIG. 7B is a picture of an SDS-PAGE gel approximately equal amounts of purified proteins from the 
showing the purity of the fusion protein after elution from elution fractions of the streptavidin binding peptide-tag 
the streptavidin column (lane 2) compared to the purity of 4o purification, the His-tag purification, and the maltose- 
the E. coli lysate that was applied to the column (lane 1). binding protein purification, respectively. 
FIGS. SA-8F are schematic illustrations of the pre- FIG. 14  illustrates a detection of a streptavidin binding 
selection method. FIG. SA is an illustration of an mRNA peptide-tagged protein with streptavidin-derivatized horse- 
display template terminating in puromycin in which the radish peroxidase. The left-hand panel shows the Coomassie 
tobacco mosaic virus translation enhancer sequence (TMV), 45 Brilliant Blue staining of an SDS-Tricine PAGE gel of the 
the initiating methionine codon (AUG), and the sections of purified streptavidin binding peptide-tagged (multiply- 
the open reading frame encoding the two protein affinity tags tagged) protein and an E. coli extract. These same samples 
(FLAG and His,) are labeled. FIG. 8B is an illustration of an were also run on a different portion of the same gel and then 
mRNA display template that is free of frameshifts and transferred to a nitrocellulose membrane. The right-hand 
premature stop codons and thus encodes a full-length protein so panel shows the result of the probing of this membrane with 
containing both affinity tags. FIG. 8C illustrates an mRNA streptavidin-derivatized horseradish peroxidase. The only 
display template that has initiated internally and displays the observed signal is for the streptavidin binding peptide- 
corresponding truncated protein lacking the N-terminal tagged protein, with no staining of other proteins in the 
FLAG tag. FIG. 8D shows an mRNA display template that extract. 
has a deletion in its open reading frame and thus displays the 55 FIG. 15 is a graph showing a KD determination of a 
corresponding frameshifted protein lacking the C-terminal streptavidin binding peptide-streptavidin interaction. The y 
His, tag. FIG. 8E illustrates the reverse transcription of the axis shows the fraction of surface-bound peptide that is 
mRNA display template from FIG. 8B that was purified competed by the free streptavidin. This analysis gave a KD 
based on the presence of both protein affinity tags in the of 2.4 nM for the interaction of the streptavidin binding 
encoded protein. FIG. 8F shows the cleavage sites for Type 60 peptide sequence with streptavidin. 
11s restriction enzymes which are encoded in each cassette. 
DETAILED DESCRIPTION Ligation of pre-selected cassettes which have been cleaved 
with these enzymes yields the full-length DNA library. The present methods stem from the discovery of peptides 
FIG. 9A is the polynucleotide sequence of the vector that have unusually high affinities for streptavidin (KD of 
encoding a fusion protein containing maltose-binding 65 less than 10 pM). These peptides were selected from a 
protein, a streptavidin-binding peptide (SEQ ID No.: 35, library of randomized, non-constrained peptides using the 
FIG. 7A), and a hexahistidine tag. FIG. 9B is the amino acid mRNA display method. The high affinity of the selected 
called 2r18-19dN. FIG. 6C is the amino acid sequence of tein from lysed cells, Purity is compared to samples pro- 
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peptides was particularly surprising, given the fact that were constructed to determine which regions were necessary 
non-constrained linear peptide libraries generally do not for high affinity streptavidin-binding (FIG. 5).  Deletion of 
yield high affinity ligands to proteins, except in cases where up to 56 residues had no observable effect on the binding 
the protein normally functions in peptide recognition strength. For example, Peptide SB19-C4 retained only the 
(Clackton et al., Trends Biotech 12:173-184 (1994); Katz, s first 38 residues from the selected construct (Plus the 
Annu. Rev. Biophys. Biomol. Struct. 26:27-45, 1997). C-terminal sequence MMSGGCmG, SEQ ID No.: 36) and 
M~~~ other peptides with high affinity for streptavidin may had a dissociation constant of 4.9 nM for streptavidin (Table 
be isolated using the mRNA display method or any other 1). In contrast, N-terminal truncation mutations (Nl-N3) 
selection method, such as ribosome display (Roberts, Curr. in a lower percentage Of the encoded peptide 
69% for the truncation mutants compared to 85% for full (U.S. Pat. No. 5,821,047). 
length SB19). These results suggested that the determinants 
streptavidin-binding peptides are described in Table 1, and N-terminal 38 residues of the SB19 peptide, the sequences of these peptides are listed in FIG. 3. The first 
shown in Table 1, have a number of uses. For example, these comparison, a non-selected sequence with two HPQ motifs 
a protein of interest as a fusion protein joined to one or more one. SB19-C4 is a truncation mutant of peptide SB19 
described below, The peptides are grouped according to thl of the streptavidin-binding peptides of the invention. In one 
2o such purification method, a sample containing the fusion number of HPQ and similar tripeptide motifs they possess. protein is incubated with immobilized streptavidin. Proteins The second column shows the number of tripeptide motifs in with no or weak affinity for streptavidin are washed away, each peptide, and the number of amino acid residues sepa- and the fusion protein is then selectively eluted from the rating them. The third column represents the percentage of 
peptide binding and specifically eluting from a streptavidin streptavidin matrix by addition of biotin, a biotin analog, another streptavidin-binding peptide, or any compound that column. This percentage ranged from 8.3% to as high as 25 
Alternatively, the fusion protein may be eluted from the the control, non-selected peptide with two HPQ motifs. matrix by increasing or decreasing the pH of the buffer 
The fourth column shows the K, when known, for the applied to the matrix, 
interaction between streptavidin and the peptides, as mea- As described in detail below, this general protocol was sured in the EMSA assay described herein. The standard 30 used in a one-step purification of a fusion protein containing deviation in the K, is shown in the fifth column, based on a streptavidin-binding peptide from an E. coli extract, result- the number of independent measurements (n, shown in ing in a high yield of very pure protein. This fusion protein 
contained the first 38 amino acids of the SB19-C4 peptide, parentheses). The dissociation constant ranged from 110 nM for peptide SB5 to 4.8 nM for peptides SB2. 
35 which due to its small size was not expected to affect the 
three-dimensional structure or activity of the covalently- 
linked protein of interest. Purification of fusion proteins 
% binding Standard containing other streptavidin-binding peptides of the present 
In addition, various modifications of the above purifica- 
tion protocol would be apparent to one skilled in the art (see, 
for example, Ausubel et al., supra), and such modifications 
SB1 HPQ19HPQ 86 so 5.7 (4) are included in the invention. In particular, use of the 
streptavidin-binding peptides as affinity tags is desirable for 
SB4 HPQ43HPQ 49 45 high throughput protein production and purification. For 
SBS HPQSZHPQ 72 110 22 (6) example, purification of fusion proteins in a multi-well 
format may be conducted using magnetic streptavidin beads 
that are washed and eluted robotically. The methods of the SB6 HPL 4 HPQ 49 
SB7 HPD 7 HPQ 28 present invention may also be adapted to purify fusion 
SB8 HPQ12HPL 27 50 proteins from in vitro translation mixtures or from other 
SB9 HPQ 12 HP 64 extracts, such as those from prokaryotic, yeast, insect, or 
mammalian cells, using standard techniques. If necessary, 
SB12 HPQ 30 EPQ 73 avidin may be added to the extract to bind any free biotin in 
SB13 HPQ 32 EPQ 64 the extract before contacting a sample from the extract with 
SB14 HPQ 43 HPL 11 5s streptavidin. Allowing any free biotin to bind avidin may 
prevent biotin from competing with the streptavidin-binding SB15 QPQSOHPQ 44 92 16 (4) SB16 HPQ 74 LPQ so 
peptides for binding to streptavidin. 
If desired, the presence of a fusion protein of the invention 
SB17 8.3 in a sample may be detected by incubating the fusion protein 
SB18 58 
SB19 85 1,8 60 with streptavidin (i.e., unlabeled streptavidin or streptavidin 
SB19-C4 88 4.9 0.88 (10) that is labeled with a detectable group) under conditions that 
allow streptavidin to bind the fusion protein. Preferably, the 
unbound streptavidin is separated from the streptavidin- 
bound fusion protein. Then, the streptavidin that is bound to 
65 the fusion protein is detected. Alternatively, the streptavidin 
bound to the fusion protein is physically separated from the 
fusion protein and then detected, using standard methods. 
Opin, Chem, Bioi, 3(3):268-73, 1999), or phage display 10 specifically from the streptavidin (0.058 to 
The binding characteristics Of for binding streptavidin were spread throughout the 
column of Table 1 lists the peptide name (SB1-SB20). For 15 High affinity streptavidin-binding peptides, as those 
spaced by 19 residues (called “non-selecte#’) is listed in row peptides may be for protein purification by expressing 
88% for the selected peptides, to only 0.16% for competes with the fusion protein for binding to the matrix. 
TABLE 1 
Peptide Structure and eluting KD (nM) deviation (n) invention may be performed similarly. 
Non-selected HPQ 19 HPQ 0.16 40 
Two HPQ motifs 
SB2 HPQ19HPQ 48 4.8 0.91 (8) 
SB3 HPQ23HPQ 20 
One HPQ and one similar tripeptide motif 
SBlO HPQ21QPQ 15 
S B l l  HPQ 28 HPA 68 
One HPQ motif 
No HPQ motif 
SB20 HPL 34 
To further characterize the binding of the selected pep- 
tides to streptavidin, truncation mutants for peptide SB19 
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For example, to detect streptavidin that is bound to the and thus for full-length peptides. These mRNA displayed 
fusion protein or that has been separated from the fusion peptides are reversed transcribed to generate double- 
protein, Western or ELISAanalysis may be performed using stranded DNA. The amplified DNA is then cleaved by 
an antibody that reacts with streptavidin or that reacts with restriction enzymes. Preferably, this restriction digestion 
a compound that is covalently linked to streptavidin. If 5 removes the sequences encoding the affinity tags from the 
streptavidin is covalently linked to an enzyme, radiolabel, DNA cassettes. The cleaved DNA cassettes are then ligated 
fluorescent label, or other detectable group, the amount of to generate the full-length DNA templates. 
streptavidin may be determined using standard techniques 
based on a characteristic of the detectable group such as its fo~~ows,  
enzyme activity, radioactivity, Or fluorescence (see, for IO Generation of a Streptavidin-Binding Peptide Library 
example, Ausubel et al., Supra). Alternatively, StrePtavidin 
may be contacted with a streptavidin-binding compound that 
is covalently linked to an enzyme, radiolabel, fluorescent 
The experiments described above were carried out as 
The mRNA display method for selecting peptides or 
proteins of interest takes advantage of the translation- 
terminating antibiotic puromycin, which functions by enter- 
label, Or other detectable group, and the detectable group ing the Asite of ribosomes and forming a covalent bond with 
may be assayed as described herein. IS the nascent peptide. By covalently attaching puromycin to 
We have also developed an improved method to generate the 3’ end of an mRNA, a covalent link between a polypep- 
synthetic DNAlibraries encoding full-length proteins, which tide and its encoding message can be achieved in situ during 
may be used in a variety of selection methods to isolate in vitro translation (Roberts et al., Curr. Opin. Stmct. Biol. 
proteins with desired binding affinities or activities. The 9:521-529, 1999; Liu et  al., Methods Enzymol. 
generation of libraries of proteins containing a desired 20 318:268-293,2000). These mRNA-peptide fusions can then 
number of amino acids is often limited by the number of by purified and subjected to in vitro selection, yielding the 
internal initiation events that result in truncated proteins and isolation of novel peptide ligands. 
the number of frameshifts that result in either premature stop A DNA library encoding polypeptides of 108 amino acids 
codons or the removal of desired stop codons. For example, was synthesized as described (Cho et al., supra). The library 
during solid phase DNA synthesis, insertions and deletions 2s consisted of short cassettes concatamerized together. Each 
which cause frameshifts may occur due to imperfect COU- cassette encoded a random peptide with a pattern of polar 
pling and capping efficiencies. In addition, the random versus non-polar amino acid side chains compatible with 
regions in DNA templates may encode stop codons, result- forming an amphipathic a-helix or 0-strand (Cho et al., 
ing in premature truncation of the encoded protein. To supra). The random region was 88 amino acids long, fol- 
address these problems, we have developed a method in 30 lowed by a C-terminal invariant region containing a hexa- 
which small DNA cassettes are synthesized, and an in vitro histidine tag (FIG. 1A). 
selection using the mRNA display technology is performed The library had a complexity of 2 . 4 ~ 1 0 ’ ~  at the DNA 
to enrich the library of DNA cassettes for sequences encod- level. It was transcribed using T7 RNA polymerase (FIG. 
ing two protein affinity tags. These DNA cassettes lack lA), after which a “linker” oligonucleotide was added to the 
frameshifts and premature stop codons. The selected DNA 3s 3’ end using T4 DNA ligase as described (Liu et al., supra; 
cassettes are then cleaved with restriction enzymes and Cho et al., supra). The linker consisted of a 21 nucleotide 
ligated to generate the full-length DNA library (FIGS. long dA stretch, followed by a polyethylene glycol linker, 
SA-SF) (Cho et al., J. Mol. Biol. 297:309-319, 2000). followed by the sequence dA-dC-dC-puromycin (Liu et al., 
In one preferred embodiment of this method, mRNA supra). 
display templates that contain a translation enhancer 40 This puromycin-terminated mRNA was translated in 
sequence operably-linked to an open reading frame and that vitro, using the Ambion (Austin, Tex.) in vitro translation kit 
terminate in puromycin are generated as described previ- under standard conditions for capped mRNA. The 10 mL 
ously (Cho et al., supra). The open reading frame encodes reaction mixture was supplemented with 2 mCi 35S- 
two different protein affinity tags, such as a FLAG tag and methionine and a total methionine concentration of 10 pM. 
a hexahistidine tag Preferably, one of the tags is located at 45 The reaction mixture also included 300 nM of the library of 
the amino-terminus of the encoded peptide, and the other tag puromycin-linked mRNAmolecules. After 1 hour at 30” C., 
is located at the carboxy-terminus. The mRNA display MgC1, and KC1 were added to 20 and 710 mM, respectively, 
templates are in vitro translated to generate mRNA dis- and the reaction mixture was further incubated at room 
played peptides (Cho et al., supra). mRNA displayed pep- temperature for five minutes to increase the yield of dis- 
tides encoded by templates that do not contain frameshifts or SO played peptides. This in vitro translation produced 1 . 2 ~ 1 0 ’ ~  
premature stop codons should contain both affinity tags. In polypeptides linked via the puromycin moiety to their 
contrast, templates that contain frameshifts or premature encoding mRNAs. 
stop codons encode peptides without the C-terminal affinity These mRNA displayed peptides were then purified on 
tag (FIG. SD). Additionally, mRNA display templates that oligo-dT cellulose (which binds to the oligo-dA sequence in 
initiate internally produce peptides without the N-terminal ss the linker) to remove polypeptides not fused to mRNA. For 
affinity tag (FIG. SC). The library of mRNA displayed this purification procedure, the reaction mixture was diluted 
peptides is enriched for peptides containing both affinity tags 10-fold into oligo-dT-binding buffer (1M NaC1, 50 mM 
by purification of the mRNAdisplayed peptides based on the HEPES, 10 mM EDTA, 0.25% Triton X-100, and 5 mM 
presence of these tags (see, for example, Ausubel et al., 2-mercaptoethanol at pH 7.9) and 80 mg oligo-dT cellulose 
supra). For example, the mRNA displayed peptides may be 60 (type 7, Amersham-Pharmacia, Piscataway, N.J.) and incu- 
applied to a matrix designed to bind peptides containing one bated with agitation at 4” C. for 30 minutes. The mixture was 
of the affinity tags, and the mRNA display peptides without applied to a column (Poly-Prep chromatography column, 
the affinity tag are washed away. The mRNA display pep- Biorad, Hercules, Calif.), drained, washed with 10 mL 
tides containing the affinity tag are then eluted and applied oligo-dT-binding buffer, washed with 10 mL oligo-dT-wash 
to a second matrix designed to bind the other affinity tag. 65 buffer (300 mM NaC1,20 mM HEPES, 1 mM EDTA, 0.25% 
The mRNAdisplay peptides recovered from this purification Triton X-100, and 5 mM 2-mercaptoethanol at pH 7.9), and 
step are enriched for members containing both affinity tags washed with 1 mLof 0.5xoligo-dT-wash buffer. The mRNA- 
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displayed peptides were eluted with 4.5 mL water plus 5 mM 
2-mercaptoethanol into tubes containing Triton X-100 and 
bovine serum albumin (BSA, New England Biolabs, 
Beverly, Mass.) at final concentrations of 0.15% and 15 
pg/mL, respectively. 
The mRNA-displayed peptides that eluted from the oligo- 
dT cellulose column were further purified on Ni-NTA 
agarose, which binds to the hexahistidine tags on the 
polypeptides, to remove any mRNA not fused to polypep- 
tides. The eluted fractions from the oligo-dT cellulose 
purification were exposed to 0.5 mL Ni-NTA-agarose 
(Qiagen, Valencia, Calif.) in Ni-binding buffer [6 M guani- 
dinium chloride, 0.5 M NaC1, 100 mM sodium phosphate, 
10 mM Tris(hydroxymethyl)aminomethane, 0.1% Triton 
X-100, 5 mM 2-mercaptoethanol, 4 pg/mL tRNA 
(Boehringer-Mannheim, Indianapolis, Ind.), and 5 pgimL 
BSA at pH 8.0)] and incubated for 30 minutes at room 
temperature. The matrix was then drained, washed with 12 
column volumes Ni-binding buffer, and eluted with the same 
buffer plus 100 mM imidazole. Eluted fractions were com- 
bined and de-salted using two successive NAP columns 
(Amersham-Pharmacia, Piscataway, N.J.) equilibrated in 1 
mM Tris(hydroxymethyl)aminomethane, 0.01% Triton 
X-100, 50 pM EDTA, 0.5 mM 2-mercaptoethanol, 0.5 
pg/mL tRNA (Boehringer-Mannheim, Indianapolis, Ind.), 
and 50 pg/mL BSA at pH 7.6). 
The mRNA portion was then reverse transcribed using 
Superscript I1 (Gibco BRL, Rockville, Md.) according to the 
manufacturers instructions, except that the mRNA concen- 
tration was about 5 nM and the enzyme concentration was 
1 U/pL. To ensure a high yield in the reaction, a mixture of 
two primers were used: 1 pM of "splint" from the splinted 
ligation (Cho et al., supra), and 1 pM of the 3' PCR primer. 
After 30 minutes at 42" C., the temperature of the reaction 
mixture was raised to 50" for 2 minutes, and then cooled 
over 5 minutes to room temperature to allow gradual peptide 
folding. Finally, the contents were de-salted using NAP 
columns and subjected to scintillation counting. By com- 
paring the 35S counts of the purified, reverse transcribed 
mRNA-peptide fusions to the 35S-methionine stock and 
taking into consideration the total methionine concentration 
in the translation reaction (10 pM), the number of displayed 
peptides in this sample was determined to be 6 . 7 ~ 1 0 ~ ~ .  This 
number also represents the complexity of the library, since 
it contained virtually no redundancy (the complexity of 
puromycin-linker template used in the translation exceeds 
the number of recovered displayed peptides by a factor of 
about 35). 
Samples from the synthesis and purification of the mRNA 
displayed peptides were run on an SDS-PAGE gel, as shown 
in FIG. 1B. 
Selection of Streptavidin-Binding Peptides 
For selection of peptides with high affinity for 
streptavidin, the above mRNAdisplayed peptide library was 
incubated with immobilized streptavidin (Ultralink immo- 
bilized streptavidin plus, about 4 mgimL; Pierce, Rockford, 
Ill.) in streptavidin-binding buffer under reducing conditions 
(40 mM Tris(hydroxymethyl)aminomethane, 300 mM KC1, 
2 mM EDTA, 0.1% Triton X-100,5 mM 2-mercaptoethanol, 
100 pg/mL BSA, and 1 pg/mL tRNA at pH 7.4). The amount 
of gel used was 0.5 mL in a total volume of 5.5 mL. After 
incubating for 20 minutes at room temperature, the contents 
were loaded onto a disposable chromatography column, 
drained, washed with 14 column volumes of streptavidin- 
binding buffer, and eluted with five successive aliquots, at 10 
minutes intervals, of streptavidin-binding buffer plus 2 mM 
D-biotin (Sigma, St. Louis, Mo.) (FIG. 1A). The fraction of 
14 
the library that survived this purification was 0.08%. Elution 
fractions were combined, de-salted on NAP columns, and 
then PCR-amplified to regenerate the double-stranded DNA 
library using the described conditions and primers in a 8 mL 
5 reaction mixture (Cho et al., supra). 
This concluded the first round of selection, and the 
remaining six rounds followed the same protocol except that 
the translation was scaled down 10-fold, and the number of 
column volumes for washing the streptavidin column was 
increased (32 volumes for round 2; 40 volumes for rounds 
3, 4 and 6; and 25 volumes for rounds 5 and 7). The 
streptavidin-binding selection for rounds 5 and 7 was per- 
formed directly on the streptavidin-column eluate from the 
preceding selection rounds, without intervening amplifica- 
tion (the biotin was removed by three successive passages 
through NAP columns). PCR products amplified after the 
seventh selection round were cloned using the TOP0 TA 
cloning kit (Invitrogen, Carlsbad, Calif.), following the 
manufacture's protocol. The fraction of the library that 
bound and eluted from the streptavidin column increased in 
Characterization of the Selected Library 
The eluate from the seventh round of selection was 
amplified by PCR. The resulting PCR DNA was used to 
synthesize a library of displayed peptides to confirm that the 
zs displayed peptides, rather than the RNA or DNA portion of 
the library constructs, were responsible for the interaction 
with streptavidin. Treatment of the library with RNAse Adid 
not reduce the extent of bindingielution from the matrix 
(FIG. 2B). Also, biotin-saturated streptavidin showed no 
30 binding to the peptide library (FIG. 2B). These results 
demonstrated that the interaction of the selected peptides 
with the streptavidin matrix was specific for the unligated 
protein, rather than for any other component of the matrix. 
Sequence Analysis of Selected Peptides 
Thirty-three randomly chosen clones from the PCR DNA 
from round seven were chosen for sequencing. Twenty 
different sequences were observed (FIG. 3). Surprisingly, all 
20 sequences were frame-shifted from the intended frame 
(frame 1) to frame 3 by deletion of two nucleotides or 
40 addition of one nucleotide. The designed pattern of polar and 
non-polar residues was therefore discarded, leaving an 
unpatterned, essentially random sequence. Prior to the 
selection, about half of the library members were in frame 
1 throughout their entire open reading frames (Cho et al., 
45 supra). Frame 3 appears to have been enriched over frame 1 
due to the increased frequency of the sequence HPQ. Frame 
1 has a low incidence (1:45,000 library members) of the 
sequence HPQ due to the designed polarinon-polar pattern. 
By contrast, frame 3 had a much higher expected incidence 
SO of the HPQ sequence (1:64), similar in frequency to that of 
a library of the same length and with equal mixtures of all 
four nucleotides at each position (1:193). Also, frame 3 was 
rich in histidine, thus allowing retention on the Ni-NTA 
column. The Ni-NTApurification protocol was intended to 
ss eliminate library mRNA molecules not displaying peptide, 
but was not performed under sufficiently stringent condi- 
tions so as to eliminate peptides with small numbers of 
histidines. Frame 2 had a high incidence of stop codons. 
Nineteen of the 20 clones had at least one HPQ motif, and 
60 five clones contained two such motifs (Table 1). The clones 
were organized according to the number of times the HPQ 
and related tripeptide motifs occur (Table 1). The number of 
amino acids between the two motifs, when present, ranged 
from four to 74. 
10 
20 each round, reaching 61% at round seven (FIG. 2A). 
35 
65 Binding Afhities of Peptides 
To rapidly assay each of the 20 selected peptides to 
determine their affinity for streptavidin, a new method for 
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preparing, tagging and purifying the peptides was employed. retained on the column during the washing step and then 
For generation of the DNA-tagged peptides, plasmids con- specifically eluted with biotin. 
taining single inserts were used as templates for PCR- The dissociation constants of the selected peptides for 
amplification using the same 5' PCR primer as described for streptavidin were measuring using an electrophoretic mobil- 
the library construction (Cho et al., supra), and a new 3' s ity shift assay (EMSA). In this assay, DTP's were incubated 
p r i m e r  (5  ' - with varying amounts of pure streptavidin (Pierce Immu- 
ATAGCCGGTGCCAAGCTTGCAGCCGCCAGACCA nopure Streptavidin, Rockford, Ill.) in streptavidin-binding 
GT-3'; SEQ ID No. 30), which altered the 3' RNA sequence buffer plus 5% glycerol to increase the density of the 
to ACUGGUCUGGCGGCUGCAAGCUUGGCAC- solution so that it could collect at the bottom of the gel well. 
CGGCUAU (SEQ ID No. 31). This sequence was designed i o  After incubating at room temperature for 20 minutes, the 
to anneal to the photo-crosslinking linker, which has the reactions mixtures were moved into the cold room, where 
s e q u e n c e  5 ' - p s o r a 1 e n - they remained for 10 minutes before being carefully loaded 
TAGCCGGTG-A17-CC-puromycin-3', in which the under- onto a 10% polyacry1amide:bisacrylamide (37.5: 1, National 
lined bases are 3'-methoxy nucleotides and the remaining Diagnostics, Atlanta, Ga.) gel (thickness 0.7 mm, height 16 
bases are deoxynucleotides (the oligonucleotide was syn- is cm, width 18 cm) containing 2xTBE, 0.1% Triton X-100 
thesized using reagents from Glen Research, Sterling, Va.). and 5% glycerol. The gel, which had been pre-run for 30 
This new primer changed the constant C-terminal peptide minutes at 13 watts, and the running buffer were pre-cooled 
sequence from WSGGCHHHHHHSSA(SEQ ID No. 32) to to 4" C. Then, the gel was run in the cold room at 13 watts, 
WSGGCKLGTGY (SEQ ID No. 33), of which the last three which increased the temperature of the gel to about 20" C. 
amino acids may not be translated because they are annealed 20 The gel was run for 45 to 120 minutes, depending on the 
to the linker. Each DNA template was transcribed and gel mobility of the particular DTP. Then, the gel was fixed in 
purified as described (Cho et al., supra), and then incubated 10% acetic acid and 10% methanol for 15 minutes, trans- 
with the psoralen linker under the following conditions: 2 ferred to electrophoresis paper (Ahlstrom, Mt. Holly 
pM mRNA, 4 pM linker, 50 mM Tris(hydroxymethy1) Springs, Pa.), dried, and analyzed using a PhosphorImager 
aminomethane, 200 mM KC1, and 10 mM spermidine at pH zs (Molecular Dynamics, Sunnyvale, Calif.). 
7.4 and 70" C. for 2 minutes, and then cooled to 4" C. over The short DNA oligonucleotide tag on the DTP's allowed 
5 minutes. Samples were then placed in the cold room in a them to migrate in a native gel, and the addition of unlabeled 
96 well plate (50 pL/well), one inch above which was ligand (i.e., streptavidin) caused a mobility shift for several 
suspended a UV lamp (366 nm, Ultraviolet Products, Inc., of the clones. The concentration of DTPs was less than 1 nM 
San Gabriel, Calif., model number UVL-21) for 15 minutes. 30 in each titration, and thus the dissociation constant (K,) can 
Then, the reactions mixtures were de-salted using a G-50 be approximated by the concentration of streptavidin that 
Sephadex  spin column (Boehringer  Mannheim,  results in half of the DTP being mobility-shifted. To deter- 
Indianapolis, Ind.). The translationidisplay reactions and mine the K, several different measurements were taken in 
oligo-dT-purification were carried out as above. Finally, the range of 25-75% of DTP bound (values outside of this 
RNase A (200 ng/mL, 10 minutes, room temperature) was 3s range were unreliable due to background and close proxim- 
added to degrade the mRNA, leaving peptides fused to a ity of the bound and unbound bands in the gel). The K, was 
short DNA oligonucleotide. Complete degradation was con- determined using the equation K,=[streptavidin]*R, where 
firmed by SDS-PAGE analysis. R is the ratio of unbound to bound DTP (ratio of unshifted 
The resulting purified DNA-tagged peptides (DTP) were to shifted band). Independent measurements on gels pre- 
analyzed in a streptavidin column-binding assay, in which 40 pared at different times were used for each clone (the 
-500 pM 35S-labeled DTP were mixed with 50 pL of the number of different measurements, n, is shown in Table 1). 
streptavidin matrix in streptavidin-binding buffer, in a total Streptavidin concentrations were measured by UV,,,, using 
volume of 300 pL, and incubated for 10 minutes at room the molar extinction coefficient of 57,000 per monomer. 
temperature with agitation. Then, the contents were loaded Examples of these mobility shifts in the presence of 
onto a chromatography column. The column was drained 4s streptavidin are shown in FIG. 4A. Some clones showed 
and washed with 80 column volumes of streptavidin-binding either no shift or poorly defined bands, suggesting that the 
buffer, and then eluted with three consecutive aliquots (3 lifetime of these complexes was too short for detection using 
column volumes each) of streptavidin-binding buffer plus 2 this method. We chose five of the most well behaved clones 
mM biotin over a 15 minute period. All fractions (flow- and quantitatively examined their mobility shifts in response 
through, washes, elutions, and irreversibly bound counts) SO to a range of streptavidin concentrations. An example of a 
were analyzed by scintillation counting to determine the streptavidin titration experiment for peptide SB19 is shown 
fraction of DTP that bound streptavidin and eluted with in FIG. 4B, and the data is graphed in FIG. 4C. The 
biotin (Table 1). The non-selected clone in which two HPQ dissociation constants for the clones ranged from 110 nM to 
motifs (separated by 19 amino acids) were introduced less than 5 nM (Table 1). These surprisingly high affinities 
e n c o d e d  t h e  s e q u e n c e  M ss were comparable to those for monoclonal antibody-antigen 
DEAHPOAGPVDQADARLVQQGA interactions, demonstrating that even random, non- 
LOHHPOGDRMMSGGCKLGTGY (SEQ ID No. 34), in constrained peptide libraries can be a source of avid ligands 
which the underlined portions are identical the HPQ regions to proteins that do not normally function in peptide binding. 
of clone SB2. Dissection of Clone SB19 
Clone SB19 possessed only one HPQ motif, bound to 
comparison, two HPQ motifs, separated by 19 residues, 85% in the column binding assay, and had a K, for 
were introduced into a control, unselected member of the streptavidin of 10 nM (Table 1). A series of C-terminal 
library. The low percentage of this control peptide that truncation constructs (Cl-C4) were constructed and assayed 
specifically eluted from the streptavidin column (0.16%) in the streptavidin column-binding assay (FIG. 5 ) .  
indicated that the presence of two HPQ motifs was not 65 C-terminal truncation analysis of clone SB19 was performed 
sufficient for high affinity binding. In contrast, a greater using standard methods by amplifying the clone with the 
percentage of the selected peptides (8.3 to 88%) was original 5' primer and a series of 3' primers that truncated the 
The results of this analysis are shown in Table 1. For 60 
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sequence at various positions and also replaced two codons radation product of the fusion protein that was missing a few 
(encoding Asp and Trp) in the C-terminal constant region amino acids from either the amino- or carboxy-terminus but 
with methionine codons to increase the 35S-incorporation. retained the streptavidin-binding peptide and thus retained 
ha logous  primers were used for the N-terminal truncation the ability to bind the streptavidin column. Thirty percent of 
analysis, except that no change was made in the N-terminal 5 the fusion protein loaded onto a column containing immo- 
constant sequence. bilized streptavidin was recovered after washing the column 
Deletion of up to 56 residues had no observable effect on with 12 column volumes of buffer. Thus, the high affinity of 
the binding strength, Peptide SB19-C4 retained only the first the fusion protein for streptavidin allowed extensive wash- 
MMSGGCKLG sequence, SEQ ID No, 36), Mutating the retaining a significant amount of the desired fusion protein. More stringent conditions eliminated the contaminating 
magnitude construct c4 to M1). from the lysed induced cells was prepared in Streptavidin-binding 
N-terminal truncation constructs (Nl-N3) suggested that buffer (SBB: 300 mM KC1, 40 mM Tris(hydroxymethy~) 
binding determinants were spread throughout the N-terminal amino methane, 5 m~ 2-mercaptoethano~, 2 m~ EDTA, 
38 residues of Peptide SB19. Of the Peptides tested, 15 0.1% Triton-X 100, pH 7.4) as described above. This sample 
C4 was therefore the minimal peptide retaining full activity (e,g,, 79 mg net weight cells in 1 SBB) was applied 
in this assay. EMSA analysis of Peptide SB19-C4 confirmed directly to the immobilized streptavidin matrix (e.g., column 
high affinity streptavidin-binding, but a fraction (13%) of the volume 100 pl; Ultralink Immobilized Streptavidin plus, 
peptide was inactive even at streptavidin concentrations >1 Pierce, Rockford Ill.) and then incubated at 4" C. for 30 
pM. The majority (87%), however, had an apparent KD of 20 minutes. The matrix was then washed with 40 column 
4.9 nM after correction for the amount of inactive peptide. volumes of SBB and then eluted with 3 successive 2 column 
Purification of Fusion Protein Containing Streptavidin- volume aliquots of SBB containing 2 mM biotin for 10 
Binding Peptide minutes each. Samples of each of the lysed uninduced and 
Afusion protein containing the first 38 amino acids of the lysed induced cells, the soluble fraction, and the elution 
SB19-C4 streptavidin-binding peptide (FIG. 7A) was zs fraction were then analyzed on an 8% SDS-Tricine PAGE 
expressed in E. coli and then purified from the cell lysate. gel, and then stained with Coomassie Brilliant Blue. In a 
For the expression of the fusion protein, BL21 (DE3) cells typical experiment, 1 ml of the soluble fraction of lysed 
were transformed with a plasmid containing a Maltose induced cells was loaded onto 0.1 ml of the affinity matrix. 
Binding Protein-Streptavidin-binding Peptide-His,- Purification using the His-tag was also carried out in an 
Protein of Interest insert (FIG. 11) which encodes a fusion 30 analogous manner to the streptavidin binding peptide-tag 
protein containing, from the amino- to carboxy-terminus, procedure with the same amounts of cells and in the same 
maltose-binding protein, the first 38 residues of the SB19- volumes. The soluble fraction was prepared in His-tag 
C4 sequence, a hexahistidine tag, and another peptide called binding buffer (300 mM NaC1, 50 mM sodium phosphate, 
2r18-19dN (FIGS. 6A-6C). This insert was constructed 0.25% Triton X-100,lO mM imidazole, pH 8.0). The sample 
using standard molecular biology techniques (see, for 35 was applied directly to the Ni-column (Ni-NTA, Qiagen, 
example, Ausubel et al., supra). Each of these domains of the Valencia Calif.) and then incubated at 4" C. for 30 minutes. 
fusion protein is separated by a few amino acids to allow The matrix was then washed with 40 column volumes of the 
proper folding of the domains. same buffer containing 20 mM imidazole and then eluted 
A kanamycin-resistant colony was selected and grown with 3 successive 2 column volume aliquots of the same 
overnight in 10 ml LB media with 50 mdliter kanamycin at 40 buffer containing 250 mM imidazole for 10 minutes each. 
37" C. This starter culture was diluted 100-fold into 1000 ml Samples were analyzed as described above. 
LB with 50 mgiliter kanamycin, and the culture was grown Purification using the maltose-binding protein sequence 
at 37" C. to OD,,, of 1.6-1.8 at 37" C. Expression of the was carried out in an analogous manner to the streptavidin 
fusion protein was induced by addition of 1 mM IPTG, and binding peptide-tag procedure with the same amounts of 
the culture was grown for another two hours. The cells were 45 cells and in the same volumes. The soluble fraction was 
pelleted by centrifugation at 3000-5OOOxg for 20 minutes. prepared in maltose-binding protein binding buffer (200 mM 
The pelleted cells were resuspended in 5% of the original KC1, 20 mM HEPES, 10 mM 2-mercaptoethanol, 0.25% 
volume of a buffer appropriate for the subsequent affinity Triton X-100, pH 7.4). The sample was applied directly to 
purification method. For purification on an amylose column the amylose column (New England Biolabs, Beverly, Mass.) 
the cells were resuspended in 1 mM EDTA and MBP buffer SO and then incubated at 4" C. for 30 minutes. The matrix was 
(10 mM HEPES.HC1, 10 mM HEPES.Na', 200 mM KC1, then washed with 40 column volumes of the same buffer and 
0.25% wiw Triton X-100, and 10 mM BME at pH 7.4) and then eluted with 3 successive 2 column volume aliquots of 
frozen slowly at -20" C. overnight. The sample was thawed the same buffer containing 10 mM maltose for 10 minutes 
in the morning and sonicated on ice. The cell lysate was each. 
obtained by collection of the supernatant after centrifugation ss For detection, ten picomoles of the loaded and eluted 
at 14,OOOxg for 20 minutes at 4" C. samples from the immobilized streptavidin column, the 
To purify the fusion protein, the cell lysate was applied to Ni-column, and the amylose column was loaded onto a 12% 
a column containing immobilized streptavidin, with a capac- SDS-Tricine PAGE gel. In the adjacent lane, a whole bac- 
ity of about 1 mgiml, that had been washed with eight terial extract from BL21 (DE3) cells was loaded. The whole 
column volumes of MBP buffer. Then, the column was 60 cell extract was prepared by growing the cells to saturation 
washed with 12 column volumes of MBP buffer. The fusion in LB, removing the media by centrifugation, and 
protein was eluted with MBP buffer containing 2 mM biotin. re-suspending them in 10% of the original culture volume 
Samples of the cell lysate and eluted protein were analyzed with the SDS-PAGE protein-loading buffer. Six microliters 
by SDS-PAGE on an 8% gel (FIG. 7B). The lane containing of this extract was run on the gel. These two samples and a 
the purified protein had a band of the expected size. No other 65 molecular weight marker were run side by side on the gel in 
bands were observed, except for a faint band of slightly duplicate. After running the gel, it was stained with Coo- 
higher mobility (FIG. 7B). This band was probably a deg- massie Brilliant Blue 
38 residues from the selected construct (plus the C-terminal ing Of the to remove contaminating proteins, 
HPQ motif to HGA reduced the activity by three Orders Of protein of higher molecular weight, The soluble fraction of 
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This gel is shown in FIG. 13. A band of the correct size two purifications were extracted into the buffers recom- 
was purified using each of the three columns. Purification on mended by the manufacturers of the two matrices, as 
immobilized streptavidin gave the highest purity sample. No described above. 
other bands were visible by Coomassie Brilliant Blue- The amount of protein in the flow-throughs, washes, and 
stained SDS-Tricine PAGE gel analysis. At least one impu- s elution fractions was measured using the Bradford assay. We 
rity was detected in the Ni-NTA-purified sample, and 
several contaminants were apparent in the amylose-purified 
sample. These results suggest that the streptavidin binding 
peptide-tag provides superior purity after a single purifica- 
tion step from lysed induced cells. 
Detection of Fusion Proteins Containing Streptavidin Bind- 
ing Peptides Using Streptavidin-Derived Reagents 
Recombinant proteins containing streptavidin affinity tags 
may also be detected using reagents that bind to these 
affinity tags. A wide range of streptavidin-derivatized 
confirmed that each column was overloaded by observing 
the multiply-tagged protein in the flow-through fractions 
from each column. Purification using Ni-NTA agarose 
(His-tagiimidazole) yielded 12 mg of protein per ml of 
i o  matrix. The amylose column yielded 4.4 mg of protein per 
ml of matrix. The immobilized streptavidin column yielded 
0.5 mg of protein per ml of matrix (0.53 mgiml with a 
standard deviation of 0.07 mgiml, n=4). The overall capacity 
of immobilized streptavidin for the streptavidin binding 
is peptide-tag was therefore lower than that of the Ni-NTA 
reagents is commercially available, and as a consequence the agarose or amylose matrices for their respective tags, but 
streptavidin binding peptide-tag provides a versatile detec- significantly greater than that of immobilized antibody 
tion tool. To demonstrate the utility of this interaction, an matrices for purifying proteins upon the basis of epitope 
experiment was performed in which a recombinant protein tags. 
was probed with streptavidin-derivatized horseradish per- 20 Biacore Analysis of the Afhi ty  of a Fusion Protein for 
oxidase. Streptavidin 
In this experiment the multiply-tagged protein was puri- The SB19-C4 streptavidin-binding fusion protein was 
fied on the streptavidin column. The purified protein and an expressed and purified from E. coli. This fusion protein 
E. coli cell lysate were electrophoresed in adjacent lanes of contained, from the amino- to carboxy-terminus, maltose- 
a SDS-Tricine PAGE gel as described above. The protein on zs binding protein, the first 38 amino acids of the SB19-C4 
the gel was transferred to nitrocellulose (Trans-blot transfer sequence, and a hexahistidine tag (FIG. 9B, SEQ ID No. 41). 
medium, 0.2 pm, Biorad catalog number 162-0112) at 10 V The plasmid (FIG. 9A, SEQ ID No. 40) encoding this fusion 
for 30 minutes using the manufacturer’s instructions (Trans- protein was constructed using standard molecular biology 
blot semi-dry transfer cell, Biorad catalog number 170- techniques and used to express the fusion protein in E. coli. 
3940). Efficient protein transfer was confirmed by the pres- 30 as described above. This fusion protein was purified from 
ence of the pre-stained molecular weight markers on the the E. coli extract using amylose resin to bind the maltose- 
nitrocellulose. binding protein portion of the fusion protein and then 
After transfer, the nitrocellulose was incubated in TBS (25 Ni-NTA resin to bind the hexahistidine tag. 
mM TrisHC1, 138 mM NaC1, 2.68 mM KC1, pH 7.4) plus To measure the affinity of the fusion protein for 
0.05% Polyoxyethylene-sorbitan monolaurate (Tween-20) 3s streptavidin, the fusion protein was immobilized on a bia- 
and 3% BSA for 1 hour at room temperature. The blot was core chip through the crosslinking of free amino groups in 
then briefly rinsed with the same buffer without BSA, and the fusion protein to the biacore chip. Buffer containing 
then a streptavidin-derivatized horseradish peroxidase con- streptavidin was washed over the chip, allowing streptavidin 
jugate (Amersham-Pharmacia, product number RPN1231) to bind the immobilized fusion protein (FIG. lOB). This 
was added at a 1,000-fold dilution in TBS/O.O5% Tween- 40 resulted in an increase in the biacore response units which 
2013% BSA, and allowed to incubate for 1 hour at room are proportional to the amount of streptavidin adhering to 
temperature. The blot was then washed 3 times with TBSi the biacore chip. Then buffer without streptavidin was 
0.05% Tween-20, and then one time with TBS. The HRP washed over the chip, and the biacore response units 
substrate (3,3’,5,5’-tetramethylbenzidene, Promega catalog decreased as streptavidin dissociated from the immobilized 
number W4121) was then added according to the manufac- 4s fusion protein (FIGS. 1OA and lOB). To measure the asso- 
turers instructions, and the blot was developed for approxi- ciation rate for the binding of streptavidin to the fusion 
mately 1 minute. protein, streptavidin concentrations of 1.6, 0.8, 0.4, 0.2, 0.1, 
These results are shown in FIG. 14. The streptavidin or 0.05 pM, (lines “a” to “f’ in FIG. 10B, respectively) were 
binding peptide-tagged protein is readily observed, and no washed over the biacore chip. The buffer also contained 40 
proteins from the E. coli lysate are labeled, thus indicating SO mM Tris(hydroxymethyl)aminomethane, 300 mM KC1, 2 
the specificity of this interaction. Streptavidin-derivatized mM EDTA, 0.1% wiv Triton X-100, and 5 mM 
horseradish peroxidase and other streptavidin-derivatized 2-mercaptoethanol at pH 7.4. This data was used to calculate 
reagents therefore provide many alternative methods of an association rate, k,, of 5x1O4/Mis, as described previ- 
detecting streptavidin binding peptide-tagged proteins on ously (BIACORE X Instrument Handbook, version AA, 
membranes, plates, tissue sections, et cetera. ss Biacore AB, Uppsala Sweden, 1997). To measure the dis- 
Yield of Fusion Proteins Containing Streptavidin-Binding sociation rate, a pulse of 23,11.5, or 5.75 pM streptavidin in 
Peptides the buffer described above was administered, and then buffer 
When scaling up protein expression to one milligram and without streptavidin was washed over the chip (FIG. 1OA). 
above, the capacity and expense of the affinity matrix often This data was used to calculate an upper limit of ~ x ~ O - ~ / S  for 
begins to become important. To measure the capacity of the 60 the dissociation rate, K, (BIACORE X Instrument 
three matrices described above for their respective tag Handbook, supra). Based on these calculated association and 
sequences, each matrix was overloaded with the multiply- dissociation rates, the dissociation constant, K, for the 
tagged protein. Cells over-expressing this protein were split binding of streptavidin by this fusion protein was less than 
into three aliquots and re-suspended in different buffers 40 nM. This result confirms the high affinity binding of the 
according to the matrix that was to be used. The sample 65 SB19-C4 peptide for streptavidin that was observed in the 
applied to immobilized streptavidin was extracted into streptavidin column-binding assay and the EMSA assay 
streptavidin-binding buffer, and the samples for the other (Table 1). Additionally, this result demonstrates that this 
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peptide maintains its high affinity for streptavidin when 
expressed as part of a fusion protein. 
Spin-Filter Binding Inhibition hsay haiysis of the f i n i t y  
of a Fusion Protein for Streptavidin 
tions; denaturing conditions were used for the Ni-NTA 
purification). The resultant purified peptide was then dia- 
lyzed into streptavidin-binding buffer (SBB: 300 mM KC1, 
40 mM Tris(hydroxymethy1) amino methane, 5 mM 
7.4). The peptide was then diluted into the same buffer and 
ing Inhibition Assay (SBIA), was also utilized. This method to give a set of 50 pl samples in which the SB19-FLAG 
is especially appropriate for cases in which numerous Pro- peptide was at 200 pM and the streptavidin concentration 
teins or peptides are derived from in vitro selection tech- ranged from 30 pM to 1 pM. Each of these samples was then 
niques using immobilized targets such as phage display i o  incubated for 2 hours at 0" C. and then subsequently 
(Smith, G. P. et al. Chem. Rev. 97:391410, 1997), mRNA incubated for 1 minute with lop1 samples of the washed and 
display (Roberts et al. proc. Natl. Acad. Sei. USA dried immobilized streptavidin matrix (Ultralink Immobi- 
94:12297-12302, 1997; Liu et al, Methods Enzymol, lized Streptavidin Plus, Pierce, Rockford 111.). The flow- 
31g268-293, 2000; Keefe et Current protocols in throughs were then immediately collected by centrifugation 
Molecular Biology 2001; Keefe et al. Nature 410:715-718, 15 in a 0.2 Pm DuraPore@ SPin-filter (Millipore, &dford 
2001) or ribosome display (Jermutus et al, cUrv. oPin, Mass.), and these were counted in a scintillation counter. 
Biotechnoz, 9:391410, 1998), The principal benefit of this These data were iteratively fitted to the following equation 
method is that it allows the and specificities of y=b+c(KD/(KD+x)) in which Y was the number Of radioac- tive decompositions detected per minute in each flow- interacting proteins to be assayed before investing the time through, K, is the dissociation constant of the complex, x 
of counts per minute not competent to bind the matrix under required for conventional affinity determinations. 
35S-labeled protein generated in a cell-free translation sys- minute competent to bind the matrix under the assay con- 
tem. The labeled protein is exposed to the bead-immobilized ditions, K, b, and were iteratively determined using the 
target (in this case immobilized streptavidin), and then the 25 program Deltagraph 4.0 ( s p s s ,  Chicago 111,). 
flow-through is collected by centrifugation in a 0.2 ium In this experiment, the binding of labeled streptavidin 
DuraporeB spin-filter. The fraction of counts that pass binding peptide-tagged peptide was inhibited by pre- 
through the filter (and therefore did not bind to the column) incubation with free streptavidin (FIG. 12). In this experi- 
indicates the fraction of labeled peptide that did not bind to ment 48% of the counts bound to immobilized streptavidin 
the matrix. To determine the affinity of the interaction, the 30 in the 1 minute slurry incubation in the absence of free 
labeled protein is first exposed to a range of concentrations streptavidin competitor, and this binding was completely 
of non-immobilized target, After this mixture has reached inhibited by high concentrations (>lo0 nM) of streptavidin. 
equilibrium, it is briefly (1 minute) exposed to the bead- Analysis of the binding curve gave a KD of 2.5 nM, which 
immobilized target, and then spin-filtered as above. The compared very favorably with the KD determined by other 
initial incubation with the soluble target will compete with 35 methods. For example, the Same Peptide was Purified on a 
the binding of the radio-labeled protein to the immobilized FLAG-affinity matrix, then bound to streptavidin immobi- 
target, The amount of inhibition is directly related to the lized on a microtiter plate. The labeled streptavidin binding 
peptide-tagged peptide was incubated with a range of fraction of labeled protein that was bound to the free target streptavidin concentrations for 1 hour before being trans- before this mixture was exposed to the immobilized target. ferred to a streptavidin-coated plate and incubated for five 
By plotting the immobilized target-binding inhibition 40 minutes, The labeled peptide not bound to the plate was 
against the concentration of the free target, the K, can easily pipetted off, The binding affinity was measured by compe- 
be derived. tition with varying concentrations of streptavidin. Analysis 
Because this titration is based on the interaction of the of the binding curve gave a Kd of 2,4+/-0,1 n ~ ,  (FIG, 
protein with the free (not immobilized) target, it may be 15)(2,4 n ~ ;  wilson et proc, Natl, ~ ~ ~ d ,  sei, USA 
more accurate than methods that quantify peptide binding to 45 9813750-3755, 2001). The streptavidin binding peptide-tag 
immobilized targets. However, SBIA may underestimate the therefore bound to streptavidin with a -5,000-fold higher 
affinity if there is significant dissociation of the complex affinity than does the Strep-tag I1 (Schmidt et a1.J. Mol. Biol. 
during the brief incubation with immobilized target. The K, 255:753-66,1996). This higher affinity accounts for the fact 
corresponds to the concentration of free target that half- that, after extensive washing (with 80 column volumes), the 
inhibits the binding to the immobilized target. As long as the so yield of retained peptide using the streptavidin binding 
concentration of the labeled binder is significantly lower PePtide-tag was 2,200-fold higher than the Yield using the 
than the K, the concentration of free target may be approxi- StreP-tag 11 (Wilson et al. PrOC. Natl. Acad. SCi. 
mated as the total concentration of added target. This method 98:3750-37553 2o01). Both the strePtavidin binding 
may be generally useful for the determination of K, values peptide-tag and the Strep-tag I1 contain the tripeptide motif 
To measure the K, of the peptide described above, a 5 2-mercaptoethano1, mM EDTA, Triton-X 'O0, pH 
mixed with a range of different streptavidin concentrations second and more general method, termed a Spin-fi1ter Bind- 
required to over-express and purify them in the quantities 2o was the concentration of free streptavidin, b was the number 
the assay conditions, and c was the number of counts per In general, SBIA low concentrations ( < K ~ )  Of 
for protein-protein, protein-peptide, and protein-small mol- 55 HPQ, but the f laking se ' l~ence in the StrePtavidin binding 
peptide-tag presumably provides additional favorable con- 
Other Embodiments 
ecule complexes. 
To measure the K, of the SB19-C4 peptide, this peptide with streptavidin' 
was fused to a FLAG-tag (streptavidin binding peptide- From the foregoing description, it will be apparent that 
98:3750-3755, 2o01). Streptavidin binding peptide-FLAG 6o described herein to adopt it to various usages and conditions, 
FLAG) et  prOc. Natz. sei. variations and modifications may be made to the invention 
was then translated in the presence of 35S-labeled methion- Such embodiments are also within the scope of the follow- 
ine by in vitro translation in reticulocyte lysate according to ing claims, 
the manufacturer's instructions (Red Nova, Novagen, All publications mentioned in this specification are herein 
Madison, Wis.1 using a template concentration of 400 nM, incorporated by reference to the same extent as if each 
1 mM extra MgC1, and 100 mM extra KC1. This mixture 65 independent publication or patent application was specifi- 
was then purified successively upon the basis of the FLAG- cally and individually indicated to be incorporated by ref- 
tag and then the His-tag (using the manufacturer's instruc- erence. 
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SEQUENCE L I S T I N G  
<160>  NUMBER O F  SEQ I D  NOS: 4 1  
<210>  SEQ I D  NO 1 
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 
M e t  A s p  G l u  L y s  T h r  H i s  C y s  T h r  I l e  Ser M e t  A s n  G l y  A l a  V a l  P r o  
1 5 1 0  1 5  
L e u  V a l  P r o  H i s  H i s  H i s  P r o  G l n  G l y  A s p  P ro  L e u  A r g  L e u  L e u  H i s  
20  2 5  3 0  
A r g  P r o  G l n  P r o  A l a  L e u  L e u  V a l  A r g  H i s  P ro  G l n  G l y  A s p  L e u  V a l  
35  40 45 
A l a  L e u  V a l  G l u  H i s  H i s  G l u  G l y  V a l  A s p  A r g  G l y  L e u  V a l  A l a  L e u  
5 0  5 5  6 0  
P r o  G l u  L e u  H i s  A l a  G l u  G l u  L e u  G l y  G l u  P ro  V a l  G l y  A s p  L e u  V a l  
6 5  7 0  7 5  8 0  
G l n  G l y  P r o  V a l  G l u  G l n  V a l  G l n  G l y  V a l  V a l  A s p  A l a  L e u  V a l  T r p  
8 5  9 0  95  
A r g  L e u  P r o  P r o  Ser 
1 0 0  
<210>  SEQ I D  NO 2 
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 2 
M e t  A s p  G l u  L y s  T h r  H i s  C y s  Phe H i s  P r o  G l y  A s p  H i s  L e u  V a l  A r g  
1 5 1 0  1 5  
L e u  V a l  G l u  G l u  L e u  G l n  A l a  L e u  A l a  G l u  G l y  L e u  G l n  A r g  G l n  G l y  
20  2 5  3 0  
G l y  A r g  G l n  P r o  H i s  A r g  L e u  P r o  A r g  A r g  A r g  P r o  H i s  H i s  L e u  G l n  
35  40 45 
L e u  L e u  L e u  A s p  G l u  A l a  H i s  P r o  G l n  A l a  G l y  P r o  L e u  A r g  G l u  A r g  
5 0  5 5  6 0  
A l a  H i s  G l n  V a l  A s p  G l y  A r g  L e u  L e u  L e u  G l n  H i s  H i s  P r o  G l n  G l y  
6 5  7 0  7 5  8 0  
A s p  A r g  L e u  L e u  G l n  G l n  P r o  G l n  A s p  H i s  P ro  L e u  G l u  L e u  V a l  T r p  
8 5  9 0  95  
A r g  L e u  P r o  P r o  Ser 
1 0 0  
<210>  SEQ I D  NO 3 
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 3 
M e t  T h r  A r g  A r g  P r o  T h r  A l a  Ser Ser Ser Ser C y s  V a l  A r g  H i s  L e u  
1 5 1 0  1 5  
US 6,841,359 B2 
26 
- con t inued  
L e u  L e u  A r g  G l n  G l y  G l u  H i s  G l y  H i s  G l n  A l a  L e u  G l u  A s p  A r g  A s p  
20  2 5  3 0  
L y s  A l a  A r g  H i s  V a l  A r g  L e u  V a l  G l u  G l y  A s p  V a l  G l u  V a l  L e u  G l y  
35  40 45 
G l y  L e u  A s p  A r g  L e u  A l a  A r g  A l a  A r g  H i s  G l u  A l a  L e u  H i s  P r o  G l n  
5 0  5 5  6 0  
A l a  G l y  L e u  V a l  H i s  L e u  P r o  L e u  H i s  G l y  G l y  A s p  L e u  G l y  G l y  H i s  
6 5  7 0  7 5  8 0  
L e u  A r g  L e u  V a l  L e u  G l u  A l a  H i s  P r o  G l n  G l y  A s p  A r g  L e u  G l y  L e u  
8 5  9 0  95  
A l a  V a l  H i s  H i s  H i s  
1 0 0  
<210>  SEQ I D  NO 4 
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 4 
M e t  A s p  G l u  L y s  T h r  H i s  T r p  G l y  I l e  S e r  T h r  T r p  A r g  G l y  G l u  P r o  
1 5 1 0  1 5  
L e u  L e u  H i s  H i s  P r o  G l n  A l a  G l y  A r g  L e u  P ro  L e u  A s p  A r g  A r g  A r g  
20  2 5  3 0  
A l a  A r g  H i s  A r g  A r g  I l e  L e u  G l y  A l a  G l u  P ro  G l y  G l y  V a l  A s p  H i s  
35  40 45 
G l y  L e u  A r g  L e u  G l u  L e u  L e u  A s p  A s p  H i s  A r g  P r o  L e u  V a l  P r o  A s p  
5 0  5 5  6 0  
H i s  H i s  P r o  G l n  A r g  G l y  P r o  L e u  G l n  A r g  G l y  A s p  L e u  P r o  G l n  V a l  
6 5  7 0  7 5  8 0  
V a l  P r o  L e u  V a l  A r g  L e u  A r g  H i s  A l a  H i s  V a l  L e u  G l y  L e u  G l y  L e u  
8 5  9 0  95  
A l a  A l a  A l a  T h r  I l e  T h r  
1 0 0  
<210>  SEQ I D  NO 5 
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 5 
M e t  A s p  G l u  L y s  T h r  H i s  T r p  V a l  A s n  V a l  T y r  H i s  P r o  G l n  G l y  A s p  
1 5 1 0  1 5  
L e u  L e u  V a l  A r g  G l y  H i s  G l y  H i s  A s p  V a l  G l u  A l a  L e u  H i s  A s p  G l n  
20  2 5  3 0  
G l y  L e u  H i s  G l n  L e u  A s p  L e u  L e u  V a l  G l y  P ro  P r o  P r o  G l u  V a l  V a l  
35  40 45 
A r g  A l a  L e u  A r g  G l y  G l u  V a l  L e u  G l y  G l y  L e u  A r g  A r g  L e u  V a l  P r o  
5 0  5 5  6 0  
L e u  A s p  H i s  P r o  G l n  G l y  G l u  A l a  L e u  A s p  G l n  A l a  A r g  G l n  A r g  P r o  
6 5  7 0  7 5  8 0  
G l n  H i s  L e u  L e u  G l u  L e u  H i s  H i s  A r g  A l a  L e u  P r o  P r o  A l a  L e u  V a l  
8 5  9 0  95  
T r p  A r g  L e u  P r o  P r o  S e r  
1 0 0  
US 6,841,359 B2 
27 28 
- con t inued  
<210>  SEQ I D  NO 6 
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 6 
M e t  A s p  G l u  L y s  T h r  H i s  T r p  L e u  A s n  A s n  Phe G l u  G l u  L e u  L e u  A l a  
1 5 1 0  1 5  
A r g  L e u  A s p  G l y  L e u  A r g  G l u  G l y  G l u  A s p  H i s  P r o  L e u  V a l  L e u  A r g  
20  2 5  3 0  
H i s  H i s  P r o  G l n  G l y  A s p  G l y  L e u  L e u  A s p  G l n  P r o  L e u  G l y  A r g  H i s  
35  40 45 
A r g  A l a  L e u  A s p  G l y  G l u  V a l  A r g  G l u  G l y  A s p  A r g  P r o  L e u  A s p  G l n  
5 0  5 5  6 0  
G l y  G l y  G l u  G l u  A s p  L e u  G l y  A l a  L e u  V a l  A s p  A s p  A s p  G l y  G l u  V a l  
6 5  7 0  7 5  8 0  
L e u  A s p  G l y  L e u  V a l  H i s  V a l  G l y  V a l  H i s  V a l  H i s  A s p  P r o  L e u  V a l  
8 5  9 0  95  
C y s  G l y  C y s  H i s  H i s  H i s  
1 0 0  
<210>  SEQ I D  NO 7 
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 7 
M e t  A s p  G l u  L y s  T h r  H i s  T r p  Phe G l y  T h r  L e u  A s n  S e r  Phe P r o  T h r  
1 5 1 0  1 5  
H i s  T r p  M e t  S e r  A l a  V a l  G l y  A s n  G l y  L y s  I l e  A s p  C y s  S e r  Phe A s n  
20  2 5  3 0  
M e t  A s n  L e u  S e r  L e u  A s n  H i s  T r p  L e u  S e r  S e r  G l y  H i s  P r o  A s p  G l y  
35  40 45 
A l a  L e u  A s p  A s p  G l n  L e u  H i s  P r o  G l n  G l y  A s p  A l a  L e u  V a l  G l y  A r g  
5 0  5 5  6 0  
A s p  A s p  G l y  V a l  V a l  G l n  A l a  L e u  A r g  L e u  G l u  G l y  G l n  H i s  G l n  H i s  
6 5  7 0  7 5  8 0  
A r g  A r g  L e u  A l a  G l n  A r g  A r g  A l a  A s p  A r g  H i s  A r g  G l n  L e u  V a l  T r p  
8 5  9 0  95  
A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 8 
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 8 
M e t  A s p  G l u  L y s  T h r  H i s  C y s  T h r  I l e  G l u  L e u  A s n  Phe S e r  Phe T h r  
1 5 1 0  1 5  
H i s  T r p  L y s  L e u  H i s  H i s  H i s  P r o  G l n  G l y  A s p  A l a  L e u  L e u  A s p  A s p  
20  2 5  3 0  
US 6,841,359 B2 
30 
- con t inued  
G l y  V a l  A r g  P r o  H i s  H i s  P r o  L e u  A l a  A s p  G l u  G l y  G l y  G l y  L e u  A s p  
35  40 45 
G l n  G l y  L e u  G l y  H i s  A r g  A r g  G l y  V a l  V a l  A l a  G l u  A r g  L e u  A l a  A r g  
5 0  5 5  6 0  
A r g  A s p  P r o  G l u  V a l  L e u  G l u  G l y  L e u  V a l  G l u  A r g  H i s  A r g  G l y  L e u  
6 5  7 0  7 5  8 0  
V a l  P r o  A r g  L e u  A r g  H i s  G l y  G l y  G l u  A r g  H i s  A l a  G l u  P r o  L e u  V a l  
8 5  9 0  95  
T r p  A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 9 
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 9 
M e t  A s p  G l u  L y s  T h r  H i s  C y s  A s n  T h r  G l y  L e u  T y r  A s p  G l y  A l a  A l a  
1 5 1 0  1 5  
A s p  C y s  Phe A s n  G l u  L e u  A s n  L y s  A s p  V a l  A l a  P r o  L e u  V a l  G l u  G l y  
20  2 5  3 0  
A r g  H i s  A s p  L e u  V a l  G l u  G l y  L e u  L e u  L e u  G l u  A r g  H i s  P r o  G l n  G l y  
35  40 45 
A s p  P r o  L e u  V a l  A l a  H i s  A r g  G l n  L e u  V a l  H i s  H i s  P r o  L e u  L e u  G l y  
5 0  5 5  6 0  
A r g  G l y  G l u  A r g  H i s  A r g  A r g  A l a  L e u  V a l  P ro  G l n  G l n  G l u  H i s  G l n  
6 5  7 0  7 5  8 0  
P r o  H i s  A r g  L e u  G l n  P r o  V a l  V a l  A s p  L e u  G l y  A r g  A r g  A r g  L e u  V a l  
8 5  9 0  95  
T r p  A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 1 0  
<211>  LENGTH: 1 0 3  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 0  
M e t  A s p  G l u  L y s  T h r  H i s  T r p  H i s  G l u  A r g  A l a  G l n  G l u  L e u  V a l  G l y  
1 5 1 0  1 5  
G l y  L e u  L e u  L e u  H i s  A s p  H i s  P r o  G l n  A r g  L e u  L e u  L e u  G l u  P r o  A r g  
20  2 5  3 0  
G l y  P r o  A r g  P r o  L e u  A r g  G l y  L e u  V a l  H i s  G l u  A r g  G l y  H i s  G l n  P r o  
35  40 45 
G l n  P r o  L e u  A l a  G l y  A r g  V a l  G l u  G l u  A l a  A s p  G l y  G l y  L e u  L e u  A r g  
5 0  5 5  6 0  
A s p  G l y  G l y  G l y  G l u  L e u  G l u  P r o  L e u  V a l  A r g  G l u  G l y  G l u  A s p  H i s  
6 5  7 0  7 5  8 0  
L e u  G l u  P r o  L e u  A s p  A s p  G l u  L e u  A s p  A l a  G l y  P r o  A r g  G l y  L e u  V a l  
8 5  9 0  95  
T r p  A r g  L e u  P r o  H i s  H i s  H i s  
1 0 0  
<210>  SEQ I D  NO 1 1  
US 6,841,359 B2 
31 
- con t inued  
32 
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 1  
M e t  A s p  G l u  L y s  T h r  H i s  T r p  H i s  G l u  A r g  V a l  H i s  H i s  L e u  A l a  A s p  
1 5 1 0  1 5  
G l y  L e u  G l u  G l n  H i s  P r o  G l n  G l y  G l n  A r g  A r g  P r o  L e u  V a l  G l u  A r g  
20  2 5  3 0  
H i s  A r g  G l n  V a l  P r o  A r g  G l y  L e u  V a l  A r g  G l u  L e u  G l n  H i s  G l u  G l y  
35  40 45 
L e u  P r o  L e u  G l u  H i s  P r o  A l a  G l y  V a l  H i s  V a l  I l e  A r g  L e u  H i s  G l n  
5 0  5 5  6 0  
G l y  A s p  A s p  A r g  A s p  V a l  A s p  G l y  L e u  V a l  A s p  G l y  H i s  G l y  A r g  A s p  
6 5  7 0  7 5  8 0  
V a l  A r g  G l y  L e u  G l u  A r g  G l u  V a l  G l y  A s p  G l y  P r o  H i s  A r g  L e u  V a l  
8 5  9 0  95  
T r p  A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 1 2  
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 2  
M e t  A s p  L y s  A s p  P r o  L e u  L e u  G l u  G l u  L e u  G l u  G l u  L e u  A r g  G l u  A r g  
1 5 1 0  1 5  
L e u  V a l  H i s  H i s  P r o  G l n  G l y  G l y  L e u  L e u  P ro  L e u  A r g  G l y  G l n  V a l  
20  2 5  3 0  
G l y  H i s  A s p  A l a  G l u  A r g  L e u  G l y  A l a  G l u  V a l  A s p  A s p  L e u  A r g  G l y  
35  40 45 
G l y  L e u  L e u  A s p  G l u  P r o  G l n  A r g  A l a  V a l  A l a  G l y  L e u  H i s  H i s  V a l  
5 0  5 5  6 0  
P r o  H i s  A r g  V a l  G l y  G l n  A r g  L e u  V a l  H i s  G l u  V a l  A r g  G l u  L e u  A s p  
6 5  7 0  7 5  8 0  
G l u  G l y  L e u  L e u  A s p  G l n  A r g  A s p  A s p  L e u  A r g  G l n  A r g  L e u  V a l  T r p  
8 5  9 0  95  
A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 1 3  
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 3  
M e t  G l u  A r g  G l u  A s p  P r o  L e u  A s p  G l u  G l n  L e u  A r g  G l u  L e u  A r g  G l u  
1 5 1 0  1 5  
A l a  L e u  V a l  A s p  H i s  P r o  G l n  G l y  G l y  A l a  G l n  A l a  L e u  H i s  A r g  H i s  
20  2 5  3 0  
A s p  G l y  G l y  G l u  H i s  V a l  P r o  L e u  A r g  A r g  V a l  G l n  H i s  A r g  L e u  G l n  
35  40 45 
US 6,841,359 B2 
34 
- con t inued  
P r o  G l y  L e u  G l n  H i s  H i s  L e u  G l u  P r o  G l n  P ro  L e u  G l y  L e u  L e u  G l y  
5 0  5 5  6 0  
G l u  L e u  G l n  A l a  A r g  L e u  G l n  P r o  L e u  A l a  G l y  G l u  H i s  G l u  G l y  A s p  
6 5  7 0  7 5  8 0  
G l y  A l a  G l y  L e u  G l n  A r g  V a l  P r o  G l y  H i s  G l n  G l y  A r g  A r g  L e u  V a l  
8 5  9 0  95  
T r p  A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 1 4  
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 4  
M e t  A s p  G l u  L y s  T h r  H i s  A r g  T h r  L e u  S e r  V a l  S e r  L e u  S e r  Phe A s n  
1 5 1 0  1 5  
A s p  T r p  L e u  G l y  G l n  T h r  L y s  A l a  C y s  T r p  A r g  L e u  V a l  G l u  G l y  L e u  
20  2 5  3 0  
H i s  G l y  H i s  P r o  G l n  G l y  L e u  V a l  A r g  G l u  H i s  G l u  V a l  A s p  V a l  L e u  
35  40 45 
P r o  L e u  A l a  G l u  G l u  V a l  G l n  G l n  V a l  V a l  G l y  G l y  L e u  A l a  A s p  G l y  
5 0  5 5  6 0  
V a l  G l u  G l n  P r o  G l y  G l y  G l y  L e u  L e u  H i s  A r g  A l a  G l n  A r g  V a l  A s p  
6 5  7 0  7 5  8 0  
H i s  P r o  L e u  P r o  A s p  H i s  A l a  G l y  G l n  V a l  L e u  G l y  A r g  L e u  V a l  T r p  
8 5  9 0  95  
A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 1 5  
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 5  
M e t  A s p  G l u  L y s  T h r  H i s  T r p  L e u  G l u  A s p  L e u  L y s  G l y  V a l  L e u  L y s  
1 5 1 0  1 5  
A s p  C y s  L e u  L y s  A s p  L e u  M e t  A s p  Phe T h r  L y s  A s p  C y s  A r g  S e r  P r o  
20  2 5  3 0  
A r g  V a l  G l n  P r o  G l n  P r o  L e u  L e u  H i s  H i s  A s p  A r g  G l y  G l u  P r o  V a l  
35  40 45 
P r o  L e u  L e u  A r g  G l u  A l a  G l y  A r g  A s p  L e u  G l y  G l y  L e u  G l y  P r o  A r g  
5 0  5 5  6 0  
A l a  P r o  A r g  G l n  A l a  A r g  P r o  L e u  H i s  H i s  G l y  A r g  H i s  A s p  L e u  H i s  
6 5  7 0  7 5  8 0  
G l u  P r o  L e u  V a l  L e u  G l n  A s p  H i s  P r o  G l n  G l y  G l y  P r o  L e u  V a l  C y s  
8 5  9 0  95  
G l y  C y s  H i s  H i s  H i s  
1 0 0  
<210>  SEQ I D  NO 1 6  
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
US 6,841,359 B2 
36 
- con t inued  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 6  
M e t  A s p  G l u  L y s  T h r  H i s  T r p  V a l  L e u  G l n  L e u  H i s  P r o  G l n  G l y  A s p  
1 5 1 0  1 5  
A r g  L e u  G l y  P r o  A r g  H i s  G l y  G l y  A s p  A s p  V a l  A r g  L e u  V a l  G l y  G l n  
20  2 5  3 0  
G l y  G l u  G l y  V a l  L e u  G l u  G l y  L e u  A s p  G l y  A r g  P r o  A r g  A r g  A r g  A r g  
35  40 45 
H i s  A r g  L e u  P r o  A r g  G l u  A s p  G l u  H i s  A r g  V a l  A r g  A l a  L e u  V a l  A s p  
5 0  5 5  6 0  
G l n  V a l  A r g  A s p  L e u  A l a  G l u  A r g  L e u  V a l  G l u  G l u  V a l  A s p  G l y  G l y  
6 5  7 0  7 5  8 0  
V a l  G l u  A l a  L e u  A r g  H i s  L e u  G l y  L e u  P r o  G l n  A s p  G l u  P r o  A r g  S e r  
8 5  9 0  95  
G l y  G l y  C y s  H i s  H i s  H i s  
1 0 0  
<210>  SEQ I D  NO 1 7  
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 7  
M e t  A s p  G l u  L y s  T h r  H i s  T r p  V a l  G l y  A s p  L e u  G l n  G l u  P r o  L e u  G l y  
1 5 1 0  1 5  
P r o  L e u  H i s  G l y  G l y  V a l  G l y  G l u  V a l  P r o  G l y  G l y  L e u  V a l  L e u  A r g  
20  2 5  3 0  
H i s  H i s  P r o  G l n  A r g  A s p  A r g  L e u  V a l  A s p  G l y  V a l  G l y  P r o  H i s  G l y  
35  40 45 
A r g  A l a  L e u  A l a  A r g  A r g  P r o  H i s  A r g  V a l  V a l  G l u  G l y  L e u  H i s  H i s  
5 0  5 5  6 0  
L e u  L e u  G l n  A r g  G l y  G l y  G l u  A r g  L e u  P r o  P ro  A s p  G l y  P r o  A r g  G l n  
6 5  7 0  7 5  8 0  
L e u  G l y  L e u  L e u  G l y  G l y  G l u  L e u  A s p  A r g  A l a  A s p  P r o  A l a  L e u  V a l  
8 5  9 0  95  
T r p  A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 1 8  
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 8  
M e t  A s p  G l u  L y s  T h r  H i s  C y s  A l a  V a l  A s n  V a l  A s n  V a l  G l y  L e u  T h r  
1 5 1 0  1 5  
H i s  T r p  C y s  H i s  A r g  V a l  A l a  H i s  L e u  G l n  P ro  L e u  A s p  P r o  H i s  P r o  
20  2 5  3 0  
G l n  G l y  A s p  H i s  L e u  A r g  L e u  G l u  P r o  L e u  G l y  H i s  A l a  L e u  V a l  A s p  
35  40 45 
P r o  L e u  V a l  G l n  G l y  V a l  G l u  G l u  V a l  V a l  A r g  P r o  L e u  G l n  L e u  A s p  
5 0  5 5  6 0  
US 6,841,359 B2 
37 38 
- con t inued  
V a l  G l y  V a l  G l n  A r g  V a l  A l a  L e u  V a l  G l u  G l n  V a l  A l a  G l u  V a l  G l y  
6 5  7 0  7 5  8 0  
G l u  G l y  L e u  A s p  H i s  G l u  A l a  G l y  G l n  A l a  H i s  G l y  A l a  L e u  V a l  T r p  
8 5  9 0  95  
A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 1 9  
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 9  
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  1 5  
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  
20  2 5  3 0  
G l n  G l y  G l n  A r g  G l u  P r o  L e u  V a l  G l n  G l u  V a l  G l u  A s p  V a l  A s p  G l u  
35  40 45 
G l y  L e u  V a l  G l n  A s p  L e u  H i s  G l y  V a l  V a l  A l a  G l y  L e u  L e u  A s p  P r o  
5 0  5 5  6 0  
V a l  G l u  L y s  L e u  L e u  T h r  A s p  T r p  Phe L y s  L y s  Phe L y s  A s n  V a l  S e r  
6 5  7 0  7 5  8 0  
L y s  A s p  C y s  L y s  M e t  T h r  Phe T y r  L e u  G l u  M e t  T y r  A s p  T r p  S e r  G l y  
8 5  9 0  95  
G l y  C y s  H i s  H i s  H i s  
1 0 0  
<210>  SEQ I D  NO 2 0  
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 2 0  
M e t  A s n  G l u  L y s  T h r  H i s  C y s  L y s  L e u  A s n  Phe L y s  V a l  A s n  I l e  A l a  
1 5 1 0  1 5  
A s p  T r p  L e u  A l a  G l u  Phe H i s  G l y  G l y  G l y  G l n  G l y  L e u  L e u  G l y  A r g  
20  2 5  3 0  
A r g  A s p  G l y  V a l  V a l  G l n  A r g  L e u  V a l  A s p  G l y  V a l  G l n  G l u  A r g  V a l  
35  40 45 
G l u  A r g  L e u  A s p  A r g  A s p  P r o  G l y  L e u  G l y  A s p  L e u  A r g  L e u  G l u  L e u  
5 0  5 5  6 0  
H i s  H i s  A r g  A s p  H i s  A r g  L e u  A r g  L e u  G l y  G l y  G l u  H i s  L e u  L e u  A r g  
6 5  7 0  7 5  8 0  
A s p  H i s  P r o  L e u  G l u  P r o  A s p  A s p  H i s  L e u  V a l  V a l  G l y  G l y  L e u  V a l  
8 5  9 0  95  
T r p  A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 2 1  
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
US 6,841,359 B2 
40 
- con t inued  
<400>  SEQUENCE: 2 1  
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  1 5  
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  
20  2 5  3 0  
G l n  G l y  G l n  A r g  G l u  P r o  L e u  V a l  G l n  G l u  V a l  G l u  A s p  V a l  A s p  G l u  
35  40 45 
G l y  L e u  V a l  G l n  A s p  L e u  H i s  G l y  V a l  V a l  A l a  G l y  L e u  L e u  A s p  P r o  
5 0  5 5  6 0  
V a l  G l u  L y s  L e u  L e u  T h r  A s p  T r p  Phe L y s  L y s  Phe L y s  A s n  V a l  S e r  
6 5  7 0  7 5  8 0  
L y s  A s p  C y s  L y s  M e t  T h r  Phe T y r  L e u  G l u  M e t  T y r  A s p  T r p  S e r  G l y  
8 5  9 0  95  
G l y  C y s  L y s  L e u  G l y  
1 0 0  
<210>  SEQ I D  NO 2 2  
<211>  LENGTH: 89  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 2 2  
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  1 5  
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  
20  2 5  3 0  
G l n  G l y  G l n  A r g  G l u  P r o  L e u  V a l  G l n  G l u  V a l  G l u  A s p  V a l  A s p  G l u  
35  40 45 
G l y  L e u  V a l  G l n  A s p  L e u  H i s  G l y  V a l  V a l  A l a  G l y  L e u  L e u  A s p  P r o  
5 0  5 5  6 0  
V a l  G l u  L y s  L e u  L e u  T h r  A s p  T r p  Phe L y s  L y s  Phe L y s  A s n  V a l  S e r  
6 5  7 0  7 5  8 0  
M e t  M e t  S e r  G l y  G l y  C y s  L y s  L e u  G l y  
8 5  
<210>  SEQ I D  NO 2 3  
<211>  LENGTH: 75  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 2 3  
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  1 5  
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  
20  2 5  3 0  
G l n  G l y  G l n  A r g  G l u  P r o  L e u  V a l  G l n  G l u  V a l  G l u  A s p  V a l  A s p  G l u  
35  40 45 
G l y  L e u  V a l  G l n  A s p  L e u  H i s  G l y  V a l  V a l  A l a  G l y  L e u  L e u  A s p  P r o  
5 0  5 5  6 0  
V a l  G l u  M e t  M e t  S e r  G l y  G l y  C y s  L y s  L e u  G l y  
6 5  7 0  7 5  
<210>  SEQ I D  NO 2 4  
<211>  LENGTH: 6 1  
US 6,841,359 B2 
41 42 
- con t inued  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 2 4  
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  1 5  
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  
20  2 5  3 0  
G l n  G l y  G l n  A r g  G l u  P r o  L e u  V a l  G l n  G l u  V a l  G l u  A s p  V a l  A s p  G l u  
35  40 45 
G l y  L e u  V a l  G l n  M e t  M e t  Ser G l y  G l y  C y s  L y s  L e u  G l y  
5 0  5 5  6 0  
<210>  SEQ I D  NO 2 5  
<211>  LENGTH: 47 
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 2 5  
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  1 5  
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  
20  2 5  3 0  
G l n  G l y  G l n  A r g  G l u  P r o  M e t  M e t  Ser G l y  G l y  C y s  L y s  L e u  G l y  
35  40 45 
<210>  SEQ I D  NO 2 6  
<211>  LENGTH: 47 
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 2 6  
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  1 5  
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  G l y  
20  2 5  3 0  
A l a  G l y  G l n  A r g  G l u  P r o  M e t  M e t  Ser G l y  G l y  C y s  L y s  L e u  G l y  
35  40 45 
<210>  SEQ I D  NO 2 7  
<211>  LENGTH: 39  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 2 7  
M e t  A s p  G l y  H i s  V a l  V a l  G l u  G l y  L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  
1 5 1 0  1 5  
A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  G l n  G l y  G l n  A r g  G l u  P r o  M e t  M e t  
20  2 5  3 0  
Ser G l y  G l y  C y s  L y s  L e u  G l y  
35  
<210>  SEQ I D  NO 2 8  
<211>  LENGTH: 89  
US 6,841,359 B2 
44 
- con t inued  
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: selected pept ide  
< 4 0 0 >  SEQUENCE: 28 
M e t  A s p  G l u  G l y  L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  
1 5 1 0  15 
G l u  H i s  H i s  P r o  G l n  G l y  G l n  A r g  G l u  P r o  L e u  V a l  G l n  G l u  V a l  G l u  
20 2 5  3 0  
A s p  V a l  A s p  G l u  G l y  L e u  V a l  G l n  A s p  L e u  H i s  G l y  V a l  V a l  A l a  G l y  
3 5  4 0  4 5  
L e u  L e u  A s p  P r o  V a l  G l u  L y s  L e u  L e u  T h r  A s p  T r p  Phe L y s  L y s  Phe 
5 0  55 60 
L y s  A s n  V a l  S e r  L y s  A s p  C y s  L y s  M e t  T h r  Phe T y r  L e u  G l u  M e t  T y r  
6 5  7 0  7 5  80 
A s p  T r p  S e r  G l y  G l y  C y s  L y s  L e u  G l y  
8 5  
< 2 1 0 >  SEQ I D  NO 2 9  
< 2 1 1 >  LENGTH: 29 
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: selected pept ide  
< 4 0 0 >  SEQUENCE: 29 
M e t  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  G l n  G l y  
1 5 1 0  15 
G l n  A r g  G l u  P r o  M e t  M e t  S e r  G l y  G l y  C y s  L y s  L e u  G l y  
20 2 5  
< 2 1 0 >  SEQ I D  NO 3 0  
< 2 1 1 >  LENGTH: 3 5  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: p r i m e r  
< 4 0 0 >  SEQUENCE: 3 0  
a tagccggtg  ccaagct tgc  agccgccaga ccagt  
< 2 1 0 >  SEQ I D  NO 3 1  
< 2 1 1 >  LENGTH: 3 5  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: p r i m e r  
< 4 0 0 >  SEQUENCE: 3 1  
acuggucugg cggcugcaag cuuggcaccg gcuau 
< 2 1 0 >  SEQ I D  NO 3 2  
< 2 1 1 >  LENGTH: 1 4  
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: selected pept ide  
< 4 0 0 >  SEQUENCE: 3 2  
T r p  S e r  G l y  G l y  C y s  H i s  H i s  H i s  H i s  H i s  H i s  S e r  S e r  A l a  
1 5 1 0  
3 5  
3 5  
US 6,841,359 B2 
46 
- con t inued  
< 2 1 0 >  SEQ I D  NO 33  
< 2 1 1 >  LENGTH: 11 
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: designed pept ide  
< 4 0 0 >  SEQUENCE: 33  
T r p  Ser G l y  G l y  C y s  L y s  L e u  G l y  T h r  G l y  T y r  
1 5 1 0  
< 2 1 0 >  SEQ I D  NO 3 4  
< 2 1 1 >  LENGTH: 4 4  
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: designed pept ide  
< 4 0 0 >  SEQUENCE: 3 4  
M e t  A s p  G l u  A l a  H i s  P r o  G l n  A l a  G l y  P r o  V a l  A s p  G l n  A l a  A s p  A l a  
1 5 1 0  15 
A r g  L e u  V a l  G l n  G l n  G l y  A l a  L e u  G l n  H i s  H i s  P r o  G l n  G l y  A s p  A r g  
20 2 5  3 0  
M e t  M e t  Ser G l y  G l y  C y s  L y s  L e u  G l y  T h r  G l y  T y r  
35 4 0  
< 2 1 0 >  SEQ I D  NO 35 
< 2 1 1 >  LENGTH: 38 
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: selected pept ide  
< 4 0 0 >  SEQUENCE: 35 
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  15 
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  
20 2 5  3 0  
G l n  G l y  G l n  A r g  G l u  P r o  
35 
< 2 1 0 >  SEQ I D  NO 3 6  
< 2 1 1 >  LENGTH: 9 
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: designed pept ide  
< 4 0 0 >  SEQUENCE: 3 6  
M e t  M e t  Ser G l y  G l y  C y s  L y s  L e u  G l y  
1 5 
< 2 1 0 >  SEQ I D  NO 3 7  
< 2 1 1 >  LENGTH: 6 6 8 8  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: p l a s m i d  
< 4 0 0 >  SEQUENCE: 3 7  
a t c c g g a t a t  a g t t c c t c c t  t t cagcaaaa  aacccctcaa g a c c c g t t t a  gaggccccaa 6 0  
g g g g t t a t g c  t a g t t a t t g c  tcagcggtgg  cagcagccaa c t c a g c t t c c  t t t c g g g c t t  1 2 0  
t g t t a g c a g c  cggatc tcag  t g g t g g t g g t  g g t g g t g c t c  gagtgcggcc g c a a g c t t t t  1 8 0  
US 6,841,359 B2 
47 48 
- con t inued  
a g t c g t c a t g  t c c a t g a t a g  g t g t c g t c c c  cgata tcaat  g c t a t t g t t a  aagcaggtct  
t a c a c a t g t t  a tagatcc tc  a a a t g c t t g t  t c t t c a c c t t  ccagt tccgg ggagccacct 
t g c a t t t c a c  acaagggtcc a t g c t a c c t c  ggggtaccaa gaat tcg tga  t g a t g g t g a t  
ggtgaccgga t c c t g g t t c a  c g t t g a c c t t  g tgggtga tg  c t c c a g t c g t  gcacgaagt t  
g t t c a a g t t c  cccagccagt cc t tcaacaa cgtgtccacc tcgccaacca g t g g t c t t c t  
cg tcca tccc  tgagccgcta cctcctgagc t c g a a t t a g t  c t g c g c g t c t  t t c a g g g c t t  
catcgacagt  ctgacgaccg c tggcggcgt  tgatcaccgc agtacgcacg gcataccaga 
aagcggacat c tgcgggatg t t c g g c a t g a  t t t c a c c t t t  c t g g g c g t t t  t c c a t t g t g g  
cggcaatacg t g g a t c t t t c  g c c a a c t c t t  cc tcgtaaga c t t c a g c g c t  acggcaccca 
g c g g t t t g t c  t t t a t t a a c c  gct tccagac c t t c a t c a g t  cagcagatag t t t t c g a g g a  
a c t c t t t t g c  c a g c t c t t t g  t t c g g a c t g g  cggcgt taa t  acc tgcgc tc  agcacgccaa 
cgaacggt t t  ggatgg t tga  ccct tgaagg tcggcagtac cg t tacacca t a a t t c a c t t  
t g c t g g t g t c  ga tg t tggac  catgcccacg ggccgt tga t  g g t c a t c g c t  g t t t c g c c t t  
ta t taaaggc a g c t t c t g c g  a tggagtaa t  c g g t g t c t g c  a t t c a t g t g t  t t g t t t t t a a  
tcaggtcaac caggaaggtc agacccgct t  tcgcgccagc g t t a t c c a c g  c c c a c g t c t t  
t a a t g t c g t a  c t t g c c g t t t  t c a t a c t t g a  acgcataacc cccgtcagca gcaatcagcg 
gccaggtgaa g t a c g g t t c t  tgcaggt tga  acatcagcgc g c t c t t a c c t  t t c g c t t t c a  
g t t c t t t a t c  cagcgccggg a t c t c t t c c c  a g g t t t t t g g  cgggt tcggc a g c a g a t c t t  
t g t t a t a a a t  cagcgataac gct tcaacag cgatcgggta agcaatcagc t t g c c g t t g t  
aacgtacggc atcccaggta aacggataca g c t t g t c c t g  g a a c g c t t t g  tccggggtga 
t t t c a g c c a a  caggccagat tgagcgtagc caccaaagcg g t c g t g t g c c  cagaagataa 
tg tcagggcc a t c g c c a g t t  gccgcaacct g t g g g a a t t t  c t c t t c c a g t  t t a t c c g g a t  
gctcaacggt  g a c t t t a a t t  c c g g t a t c t t  t c t c g a a t t t  c t t a c c g a c t  tcagcgagac 
c g t t a t a g c c  t t t a t c g c c g  t t a a t c c a g a  t t a c c a g t t t  a c c t t c t t c g  a t t c c c a t g g  
t a t a t c t c c t  t c t t a a a g t t  aaacaaaatt a t t t c t a g a g  g g g a a t t g t t  a tccgc tcac  
a a t t c c c c t a  tag tgagtcg  t a t t a a t t t c  gcgggatcga g a t c t c g a t c  c tc tacgccg 
gacgcatcgt  ggccggcatc accggcgcca caggtgcggt  tgctggcgcc t a t a t c g c c g  
acatcaccga tggggaagat cgggctcgcc a c t t c g g g c t  catgagcgct  t g t t t c g g c g  
t g g g t a t g g t  ggcaggcccc gtggccgggg gac tg t tggg cgccatc tcc  t t g c a t g c a c  
c a t t c c t t g c  ggcggcggtg ctcaacggcc t c a a c c t a c t  actgggctgc t t c c t a a t g c  
aggagtcgca taagggagag cgtcgagatc ccggacacca tcgaatggcg c a a a a c c t t t  
cgcggtatgg catgatagcg cccggaagag a g t c a a t t c a  gggtggtgaa tg tgaaacca 
g t a a c g t t a t  acgatgtcgc agagtatgcc g g t g t c t c t t  a tcagaccgt  t t c c c g c g t g  
gtgaaccagg ccagccacgt t t c t g c g a a a  acgcgggaaa aagtggaagc ggcgatggcg 
gagc tgaat t  aca t tcccaa ccgcgtggca caacaactgg cgggcaaaca g t c g t t g c t g  
a t t g g c g t t g  ccacctccag t c t g g c c c t g  cacgcgccgt c g c a a a t t g t  cgcggcgat t  
aaatc tcgcg ccgatcaact  gggtgccagc g t g g t g g t g t  cgatggtaga acgaagcggc 
gtcgaagcct  gtaaagcggc ggtgcacaat  c t t c t c g c g c  aacgcgtcag tgggc tga tc  
a t t a a c t a t c  cgctggatga ccaggatgcc a t t g c t g t g g  aagc tgcc tg  c a c t a a t g t t  
c c g g c g t t a t  t t c t t g a t g t  c tc tgaccag acacccatca a c a g t a t t a t  t t t c t c c c a t  
2 4 0  
3 0 0  
3 6 0  
4 2 0  
4 8 0  
5 4 0  
6 0 0  
6 6 0  
7 2 0  
7 8 0  
8 4 0  
9 0 0  
9 6 0  
1 0 2 0  
1 0 8 0  
1 1 4 0  
1 2 0 0  
1 2 6 0  
1 3 2 0  
1 3 8 0  
1 4 4 0  
1 5 0 0  
1 5 6 0  
1 6 2 0  
1 6 8 0  
1 7 4 0  
1 8 0 0  
1 8 6 0  
1 9 2 0  
1 9 8 0  
2 0 4 0  
2 1 0 0  
2 1 6 0  
2 2 2 0  
2 2 8 0  
2 3 4 0  
2 4 0 0  
2 4 6 0  
2 5 2 0  
2 5 8 0  
US 6,841,359 B2 
50 
- con t inued  
gaagacggta cgcgactggg cgtggagcat  c t g g t c g c a t  tgggtcacca gcaaatcgcg 
c t g t t a g c g g  gcccat taag t t c t g t c t c g  gcgcgtc tgc g t c t g g c t g g  c tggcataaa 
t a t c t c a c t c  gcaatcaaat  tcagccgata gcggaacggg aaggcgactg gagtgccatg 
t c c g g t t t t c  aacaaaccat gcaaatgctg aatgagggca t c g t t c c c a c  t g c g a t g c t g  
gt tgccaacg atcagatggc gctgggcgca atgcgcgcca t t a c c g a g t c  cgggctgcgc 
g t tgg tgcgg a t a t c t c g g t  agtgggatac gacgataccg aagacagctc a t g t t a t a t c  
ccgccgt taa  ccaccatcaa a c a g g a t t t t  cgcc tgc tgg  ggcaaaccag cgtggaccgc 
t t g c t g c a a c  t c t c t c a g g g  ccaggcggtg aagggcaatc a g c t g t t g c c  c g t c t c a c t g  
gtgaaaagaa aaaccaccct ggcgcccaat acgcaaaccg c c t c t c c c c g  cgcgt tggcc 
g a t t c a t t a a  tgcagctggc acgacaggt t  t cccgac tgg  aaagcgggca gtgagcgcaa 
cgcaat taa t  g taagt tagc  t c a c t c a t t a  ggcaccggga tc tcgaccga t g c c c t t g a g  
agcct tcaac ccagtcagct  c c t t c c g g t g  ggcgcggggc a t g a c t a t c g  tcgccgcac t  
t a t g a c t g t c  t t c t t t a t c a  t g c a a c t c g t  aggacaggtg ccggcagcgc t c t g g g t c a t  
t t t c g g c g a g  g a c c g c t t t c  gctggagcgc gacgatgatc ggcctgtcgc t t g c g g t a t t  
c g g a a t c t t g  cacgccctcg c t c a a g c c t t  c g t c a c t g g t  cccgccacca a a c g t t t c g g  
cgagaagcag g c c a t t a t c g  ccggcatggc ggccccacgg gtgcgcatga t c g t g c t c c t  
g tcg t tgagg acccggctag gctggcgggg t t g c c t t a c t  ggt tagcaga atgaatcacc 
gatacgcgag cgaacgtgaa gcgactgctg ctgcaaaacg t c t g c g a c c t  gagcaacaac 
a tgaatgg tc  t t c g g t t t c c  g t g t t t c g t a  aagtctggaa acgcggaagt cagcgccctg 
c a c c a t t a t g  t t c c g g a t c t  gcatcgcagg a t g c t g c t g g  c t a c c c t g t g  gaacacctac 
a t c t g t a t t a  acgaagcgct ggcat tgacc c t g a g t g a t t  t t t c t c t g g t  cccgccgcat 
ccataccgcc a g t t g t t t a c  cctcacaacg t t c c a g t a a c  c g g g c a t g t t  c a t c a t c a g t  
aacccgtatc  gtgagcatcc t c t c t c g t t t  c a t c g g t a t c  a t taccccca tgaacagaaa 
t c c c c c t t a c  acggaggcat cagtgaccaa acaggaaaaa accgccc t ta  acatggcccg 
c t t t a t c a g a  agccagacat t a a c g c t t c t  ggagaaactc aacgagctgg acgcggatga 
acaggcagac a t c t g t g a a t  cgc t tcacga ccacgctgat  g a g c t t t a c c  gcagctgcct  
c g c g c g t t t c  ggtgatgacg gtgaaaacct  c tgacacatg cagctcccgg agacggtcac 
a g c t t g t c t g  taagcggatg ccgggagcag acaagcccgt cagggcgcgt cagcgggtgt  
tggcgggtg t  cggggcgcag ccatgaccca gtcacgtagc gatagcggag t g t a t a c t g g  
c t t a a c t a t g  cggcatcaga gcagat tg ta  ctgagagtgc a c c a t a t a t g  cggtgtgaaa 
taccgcacag atgcgtaagg agaaaatacc gcatcaggcg c t c t t c c g c t  t c c t c g c t c a  
c t g a c t c g c t  gcgctcggtc  g t tcggc tgc  ggcgagcggt a tcagctcac tcaaaggcgg 
t a a t a c g g t t  atccacagaa tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc 
agcaaaaggc caggaaccgt aaaaaggccg c g t t g c t g g c  g t t t t t c c a t  aggctccgcc 
cccctgacga gcatcacaaa aatcgacgct  caagtcagag gtggcgaaac ccgacaggac 
ta taaagata  c c a g g c g t t t  ccccctggaa g c t c c c t c g t  g c g c t c t c c t  g t tccgaccc  
t g c c g c t t a c  cggatacctg t c c g c c t t t c  t c c c t t c g g g  aagcgtggcg c t t t c t c a t a  
gc tcacgc tg  t a g g t a t c t c  a g t t c g g t g t  a g g t c g t t c g  c tccaagctg  ggc tg tg tgc  
acgaaccccc cgt tcagccc gaccgctgcg c c t t a t c c g g  t a a c t a t c g t  c t t g a g t c c a  
2 6 4 0  
2 7 0 0  
2 7 6 0  
2 8 2 0  
2 8 8 0  
2 9 4 0  
3 0 0 0  
3 0 6 0  
3 1 2 0  
3 1 8 0  
3 2 4 0  
3 3 0 0  
3 3 6 0  
3 4 2 0  
3 4 8 0  
3 5 4 0  
3 6 0 0  
3 6 6 0  
3 7 2 0  
3 7 8 0  
3 8 4 0  
3 9 0 0  
3 9 6 0  
4 0 2 0  
4 0 8 0  
4 1 4 0  
4 2 0 0  
4 2 6 0  
4 3 2 0  
4 3 8 0  
4 4 4 0  
4 5 0 0  
4 5 6 0  
4 6 2 0  
4 6 8 0  
4 7 4 0  
4 8 0 0  
4 8 6 0  
4 9 2 0  
US 6,841,359 B2 
52 
- con t inued  
acccggtaag acacgactta tcgccactgg cagcagccac tggtaacagg attagcagag 
cgaggtatgt aggcggtgct acagagttct tgaagtggtg gcctaactac ggctacacta 
gaaggacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga aaaagagttg 
gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt gtttgcaagc 
agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt tctacggggt 
ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaac aataaaactg 
tctgcttaca taaacagtaa tacaaggggt gttatgagcc atattcaacg ggaaacgtct 
tgctctaggc cgcgattaaa ttccaacatg gatgctgatt tatatgggta taaatgggct 
cgcgataatg tcgggcaatc aggtgcgaca atctatcgat tgtatgggaa gcccgatgcg 
ccagagttgt ttctgaaaca tggcaaaggt agcgttgcca atgatgttac agatgagatg 
gtcagactaa actggctgac ggaatttatg cctcttccga ccatcaagca ttttatccgt 
actcctgatg atgcatggtt actcaccact gcgatccccg ggaaaacagc attccaggta 
ttagaagaat atcctgattc aggtgaaaat attgttgatg cgctggcagt gttcctgcgc 
cggttgcatt cgattcctgt ttgtaattgt ccttttaaca gcgatcgcgt atttcgtctc 
gctcaggcgc aatcacgaat gaataacggt ttggttgatg cgagtgattt tgatgacgag 
cgtaatggct ggcctgttga acaagtctgg aaagaaatgc ataaactttt gccattctca 
ccggattcag tcgtcactca tggtgatttc tcacttgata accttatttt tgacgagggg 
aaattaatag gttgtattga tgttggacga gtcggaatcg cagaccgata ccaggatctt 
gccatcctat ggaactgcct cggtgagttt tctccttcat tacagaaacg gctttttcaa 
aaatatggta ttgataatcc tgatatgaat aaattgcagt ttcatttgat gctcgatgag 
tttttctaag aattaattca tgagcggata catatttgaa tgtatttaga aaaataaaca 
aataggggtt ccgcgcacat ttccccgaaa agtgccacct gaaattgtaa acgttaatat 
tttgttaaaa ttcgcgttaa atttttgtta aatcagctca ttttttaacc aataggccga 
aatcggcaaa atcccttata aatcaaaaga atagaccgag atagggttga gtgttgttcc 
agtttggaac aagagtccac tattaaagaa cgtggactcc aacgtcaaag ggcgaaaaac 
cgtctatcag ggcgatggcc cactacgtga accatcaccc taatcaagtt ttttggggtc 
gaggtgccgt aaagcactaa atcggaaccc taaagggagc ccccgattta gagcttgacg 
gggaaagccg gcgaacgtgg cgagaaagga agggaagaaa gcgaaaggag cgggcgctag 
ggcgctggca agtgtagcgg tcacgctgcg cgtaaccacc acacccgccg cgcttaatgc 
gccgctacag ggcgcgtccc attcgcca 
<210>  SEQ ID NO 3 8  
<211>  LENGTH: 479  
<212>  TYPE: PRT 
<213>  ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: Designed protein 
<400>  SEQUENCE: 3 8  
Met Gly Ile Glu Glu Gly Lys Leu Val Ile Trp Ile Asn Gly Asp Lys 
1 5 1 0  1 5  
Gly Tyr Asn Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp Thr 
20  2 5  3 0  
4 9 8 0  
5 0 4 0  
5 1 0 0  
5 1 6 0  
5 2 2 0  
5 2 8 0  
5 3 4 0  
5 4 0 0  
5 4 6 0  
5 5 2 0  
5 5 8 0  
5 6 4 0  
5 7 0 0  
5 7 6 0  
5 8 2 0  
5 8 8 0  
5 9 4 0  
6 0 0 0  
6 0 6 0  
6 1 2 0  
6 1 8 0  
6 2 4 0  
6 3 0 0  
6 3 6 0  
6 4 2 0  
6 4 8 0  
6 5 4 0  
6 6 0 0  
6 6 6 0  
6 6 8 8  
Gly Ile Lys Val Thr Val Glu His Pro Asp Lys Leu Glu Glu Lys Phe 
35  40 45 
US 6,841,359 B2 
54 
- con t inued  
P r o  G l n  V a l  A l a  A l a  T h r  G l y  A s p  G l y  P r o  A s p  I l e  I l e  Phe T r p  A l a  
5 0  5 5  6 0  
H i s  A s p  A r g  Phe G l y  G l y  T y r  A l a  G l n  S e r  G l y  L e u  L e u  A l a  G l u  I l e  
6 5  7 0  7 5  8 0  
T h r  P r o  A s p  L y s  A l a  Phe G l n  A s p  L y s  L e u  T y r  P r o  Phe T h r  T r p  A s p  
8 5  9 0  95  
A l a  V a l  A r g  T y r  A s n  G l y  L y s  L e u  I l e  A l a  T y r  P r o  I l e  A l a  V a l  G l u  
1 0 0  1 0 5  1 1 0  
A l a  L e u  S e r  L e u  I l e  T y r  A s n  L y s  A s p  L e u  L e u  P r o  A s n  P r o  P r o  L y s  
1 1 5  1 2 0  1 2 5  
T h r  T r p  G l u  G l u  I l e  P r o  A l a  L e u  A s p  L y s  G l u  L e u  L y s  A l a  L y s  G l y  
1 3 0  1 3 5  1 4 0  
L y s  S e r  A l a  L e u  M e t  Phe A s n  L e u  G l n  G l u  P ro  T y r  Phe T h r  T r p  P r o  
1 4 5  1 5 0  1 5 5  1 6 0  
L e u  I l e  A l a  A l a  A s p  G l y  G l y  T y r  A l a  Phe L y s  T y r  G l u  A s n  G l y  L y s  
1 6 5  1 7 0  1 7 5  
T y r  A s p  I l e  L y s  A s p  V a l  G l y  V a l  A s p  A s n  A l a  G l y  A l a  L y s  A l a  G l y  
1 8 0  1 8 5  1 9 0  
L e u  T h r  Phe L e u  V a l  A s p  L e u  I l e  L y s  A s n  L y s  H i s  M e t  A s n  A l a  A s p  
1 9 5  2 0 0  2 0 5  
T h r  A s p  T y r  S e r  I l e  A l a  G l u  A l a  A l a  Phe A s n  L y s  G l y  G l u  T h r  A l a  
2 1 0  2 1 5  2 2 0  
M e t  T h r  I l e  A s n  G l y  P r o  T r p  A l a  T r p  S e r  A s n  I l e  A s p  T h r  S e r  L y s  
2 2 5  2 3 0  2 3 5  2 4 0  
V a l  A s n  T y r  G l y  V a l  T h r  V a l  L e u  P r o  T h r  Phe L y s  G l y  G l n  P r o  S e r  
2 4 5  2 5 0  2 5 5  
L y s  P r o  Phe V a l  G l y  V a l  L e u  S e r  A l a  G l y  I l e  A s n  A l a  A l a  S e r  P r o  
2 6 0  2 6 5  2 7 0  
A s n  L y s  G l u  L e u  A l a  L y s  G l u  Phe L e u  G l u  A s n  T y r  L e u  L e u  T h r  A s p  
2 7 5  2 8 0  2 8 5  
G l u  G l y  L e u  G l u  A l a  V a l  A s n  L y s  A s p  L y s  P ro  L e u  G l y  A l a  V a l  A l a  
2 9 0  2 9 5  3 0 0  
L e u  L y s  S e r  T y r  G l u  G l u  G l u  L e u  A l a  L y s  A s p  P r o  A r g  I l e  A l a  A l a  
3 0 5  3 1 0  3 1 5  3 2 0  
T h r  M e t  G l u  A s n  A l a  G l n  L y s  G l y  G l u  I l e  M e t  P r o  A s n  I l e  P r o  G l n  
3 2 5  3 3 0  3 3 5  
M e t  S e r  A l a  Phe T r p  T y r  A l a  V a l  A r g  T h r  A l a  V a l  I l e  A s n  A l a  A l a  
3 4 0  3 4 5  3 5 0  
S e r  G l y  A r g  G l n  T h r  V a l  A s p  G l u  A l a  L e u  L y s  A s p  A l a  G l n  T h r  A s n  
3 5 5  3 6 0  3 6 5  
S e r  S e r  S e r  G l y  G l y  S e r  G l y  S e r  G l y  M e t  A s p  G l u  L y s  T h r  T h r  G l y  
3 7 0  3 7 5  3 8 0  
T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  L e u  A l a  G l y  G l u  L e u  G l u  G l n  
3 8 5  3 9 0  3 9 5  400  
L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  G l n  G l y  G l n  A r g  G l u  P r o  G l y  
4 0 5  410  4 1 5  
S e r  G l y  H i s  H i s  H i s  H i s  H i s  H i s  G l u  Phe L e u  V a l  P r o  A r g  G l y  S e r  
420  4 2 5  4 3 0  
M e t  A s p  P r o  C y s  V a l  L y s  C y s  L y s  V a l  A l a  P ro  A r g  A s n  T r p  L y s  V a l  
4 3 5  4 4 0  4 4 5  
L y s  A s n  L y s  H i s  L e u  A r g  I l e  T y r  A s n  M e t  C y s  L y s  T h r  C y s  Phe A s n  
4 5 0  4 5 5  4 6 0  
A s n  S e r  I l e  A s p  I l e  G l y  A s p  A s p  T h r  T y r  H i s  G l y  H i s  A s p  A s p  
US 6,841,359 B2 
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- con t inued  
4 6 5  4 7 0  4 7 5  
<210>  SEQ I D  NO 3 9  
<211>  LENGTH: 47 
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: S e l e c t e d  p e p t i d e  
<400>  SEQUENCE: 3 9  
M e t  Asp Pro  Cys Val Lys Cys Lys Val Ala Pro Arg Asn Trp Lys Val 
1 5 1 0  1 5  
Lys Asn Lys H i s  Leu Arg I l e  Tyr Asn M e t  Cys Lys Thr Cys Phe A s n  
20  2 5  3 0  
Asn S e r  I l e  Asp I l e  Gly Asp Asp Thr Tyr H i s  Gly H i s  Asp Asp 
35  40 45 
<210>  SEQ I D  NO 4 0  
<211>  LENGTH: 6 5 4 4  
<212>  TYPE: DNA 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: plasmid 
<400>  SEQUENCE: 4 0  
a t c c g g a t a t  a g t t c c t c c t  t t c a g c a a a a  a a c c c c t c a a  g a c c c g t t t a  gaggccccaa 
g g g g t t a t g c  t a g t t a t t g c  tcagcggtgg  cagcagccaa c t c a g c t t c c  t t t c g g g c t t  
t g t t a g c a g c  c g g a t c t c a g  t g g t g g t g g t  g g t g g t g c t c  gagtgcggcc g c a a g c t t c a  
gctgcgaagc t t a t t a g a a t  t c g t g a t g a t  g g t g a t g g t g  a c c g g a t c c t  g g t t c a c g t t  
g a c c t t g t g g  g t g a t g c t c c  a g t c g t g c a c  g a a g t t g t t c  a a g t t c c c c a  g c c a g t c c t t  
caacaacgtg  t c c a c c t c g c  caaccagtgg  t c t t c t c g t c  c a t c c c t g a g  c c g c t a c c t c  
c t g a g c t c g a  a t t a g t c t g c  g c g t c t t t c a  g g g c t t c a t c  g a c a g t c t g a  cgaccgctgg 
c g g c g t t g a t  caccgcagta  cgcacggcat  accagaaagc g g a c a t c t g c  g g g a t g t t c g  
g c a t g a t t t c  a c c t t t c t g g  g c g t t t t c c a  t t g t g g c g g c  a a t a c g t g g a  t c t t t c g c c a  
a c t c t t c c t c  g t a a g a c t t c  agcgctacgg cacccagcgg t t t g t c t t t a  t t a a c c g c t t  
c c a g a c c t t c  a t c a g t c a g c  a g a t a g t t t t  cgaggaactc  t t t t g c c a g c  t c t t t g t t c g  
gactggcggc g t t a a t a c c t  gcgctcagca cgccaacgaa c g g t t t g g a t  g g t t g a c c c t  
tgaaggtcgg  c a g t a c c g t t  a c a c c a t a a t  t c a c t t t g c t  g g t g t c g a t g  t t g g a c c a t g  
cccacgggcc g t t g a t g g t c  a t c g c t g t t t  c g c c t t t a t t  aaaggcagct  t c t g c g a t g g  
a g t a a t c g g t  g t c t g c a t t c  a t g t g t t t g t  t t t t a a t c a g  g tcaaccagg aaggtcagac  
c c g c t t t c g c  g c c a g c g t t a  tccacgccca  c g t c t t t a a t  g t c g t a c t t g  c c g t t t t c a t  
a c t t g a a c g c  a taacccccg  tcagcagcaa  tcagcggcca ggtgaagtac  g g t t c t t g c a  
g g t t g a a c a t  cagcgcgctc  t t a c c t t t c g  c t t t c a g t t c  t t t a t c c a g c  gccgggatc t  
c t t c c c a g g t  t t t t g g c g g g  t t c g g c a g c a  g a t c t t t g t t  a t a a a t c a g c  g a t a a c g c t t  
caacagcgat  cgggtaagca a t c a g c t t g c  c g t t g t a a c g  t a c g g c a t c c  caggtaaacg  
g a t a c a g c t t  g t c c t g g a a c  g c t t t g t c c g  g g g t g a t t t c  agccaacagg c c a g a t t g a g  
cg tagccacc  aaagcggtcg t g t g c c c a g a  a g a t a a t g t c  agggccatcg c c a g t t g c c g  
c a a c c t g t g g  g a a t t t c t c t  t c c a g t t t a t  c c g g a t g c t c  a a c g g t g a c t  t t a a t t c c g g  
t a t c t t t c t c  g a a t t t c t t a  c c g a c t t c a g  c g a g a c c g t t  a t a g c c t t t a  t c g c c g t t a a  
6 0  
2 0  
8 0  
2 4 0  
3 0 0  
3 6 0  
4 2 0  
4 8 0  
5 4 0  
6 0 0  
6 6 0  
7 2 0  
7 8 0  
8 4 0  
9 0 0  
9 6 0  
1 0 2 0  
1 0 8 0  
1 1 4 0  
1 2 0 0  
1 2 6 0  
1 3 2 0  
1 3 8 0  
1 4 4 0  
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- con t inued  
t c c a g a t t a c  c a g t t t a c c t  t c t t c g a t t c  c c a t g g t a t a  t c t c c t t c t t  aaagttaaac 
a a a a t t a t t t  ctagagggga a t t g t t a t c c  g c t c a c a a t t  c c c c t a t a g t  g a g t c g t a t t  
a a t t t c g c g g  gatcgagatc t c g a t c c t c t  acgccggacg catcgtggcc ggcatcaccg 
gcgccacagg t g c g g t t g c t  ggcgcctata tcgccgacat  caccgatggg gaagatcggg 
c t c g c c a c t t  cgggctcatg a g c g c t t g t t  tcggcgtggg t a t g g t g g c a  ggccccgtgg 
ccgggggact g t tgggcgcc a t c t c c t t g c  a t g c a c c a t t  cc t tgcggcg gcggtgctca 
acggcctcaa c c t a c t a c t g  g g c t g c t t c c  taatgcagga gtcgcataag ggagagcgtc 
gagatcccgg acaccatcga atggcgcaaa a c c t t t c g c g  g t a t g g c a t g  atagcgcccg 
gaagagagtc aa t tcagggt  gg tgaatg tg  aaaccagtaa c g t t a t a c g a  tg tcgcagag 
t a t g c c g g t g  t c t c t t a t c a  g a c c g t t t c c  cgcgtggtga accaggccag c c a c g t t t c t  
gcgaaaacgc gggaaaaagt ggaagcggcg atggcggagc t g a a t t a c a t  tcccaaccgc 
gtggcacaac aactggcggg caaacagtcg t t g c t g a t t g  gcgt tgccac c t c c a g t c t g  
gccctgcacg cgccgtcgca a a t t g t c g c g  gcgat taaat  ctcgcgccga t c a a c t g g g t  
gccagcgtgg t g g t g t c g a t  ggtagaacga agcggcgtcg aagcctgtaa agcggcggtg 
c a c a a t c t t c  tcgcgcaacg cgtcagtggg c t g a t c a t t a  a c t a t c c g c t  ggatgaccag 
g a t g c c a t t g  ctgtggaagc t g c c t g c a c t  a a t g t t c c g g  c g t t a t t t c t  t g a t g t c t c t  
gaccagacac ccatcaacag t a t t a t t t t c  tcccatgaag acggtacgcg actgggcgtg 
gagcatc tgg t c g c a t t g g g  tcaccagcaa a t c g c g c t g t  tagcgggccc a t t a a g t t c t  
g tc tcggcgc g t c t g c g t c t  ggctggctgg ca taaata tc  tcac tcgcaa t c a a a t t c a g  
ccgatagcgg aacgggaagg cgactggagt  gcca tg tccg  g t t t t c a a c a  aaccatgcaa 
a tgc tgaatg  agggcatcgt  tcccac tgcg  a t g c t g g t t g  ccaacgatca gatggcgctg 
ggcgcaatgc gcgccat tac cgagtccggg c t g c g c g t t g  g tgcggata t  c t c g g t a g t g  
ggatacgacg ataccgaaga c a g c t c a t g t  t a t a t c c c g c  cgt taaccac catcaaacag 
g a t t t t c g c c  tgctggggca aaccagcgtg gaccgct tgc t g c a a c t c t c  tcagggccag 
gcggtgaagg gcaatcagct  g t t g c c c g t c  t c a c t g g t g a  aaagaaaaac caccctggcg 
cccaatacgc aaaccgcctc tccccgcgcg t t g g c c g a t t  c a t t a a t g c a  gctggcacga 
c a g g t t t c c c  gactggaaag cgggcagtga gcgcaacgca a t t a a t g t a a  g t t a g c t c a c  
t c a t t a g g c a  ccgggatctc  gaccgatgcc c t tgagagcc t tcaacccag t c a g c t c c t t  
ccggtgggcg cggggcatga c t a t c g t c g c  c g c a c t t a t g  a c t g t c t t c t  t t a t c a t g c a  
actcgtagga caggtgccgg cagcgc tc tg  g g t c a t t t t c  ggcgaggacc g c t t t c g c t g  
gagcgcgacg atgatcggcc t g t c g c t t g c  gg ta t tcgga a t c t t g c a c g  ccc tcgc tca  
a g c c t t c g t c  ac tgg tcccg  ccaccaaacg t t t c g g c g a g  aagcaggcca t t a t c g c c g g  
catggcggcc ccacgggtgc gca tga tcg t  g c t c c t g t c g  t tgaggaccc ggctaggctg 
gcggggttgc c t t a c t g g t t  agcagaatga atcaccgata cgcgagcgaa cgtgaagcga 
c t g c t g c t g c  aaaacgtc tg cgacctgagc aacaacatga a t g g t c t t c g  g t t t c c g t g t  
t t c g t a a a g t  ctggaaacgc ggaagtcagc gccctgcacc a t t a t g t t c c  g g a t c t g c a t  
cgcaggatgc t g c t g g c t a c  cctgtggaac a c c t a c a t c t  g ta t taacga agcgctggca 
t t g a c c c t g a  g t g a t t t t t c  t c t g g t c c c g  ccgcatcca t  accgccagt t  g t t t a c c c t c  
acaacgt tcc agtaaccggg c a t g t t c a t c  atcagtaacc c g t a t c g t g a  g c a t c c t c t c  
t c g t t t c a t c  g g t a t c a t t a  cccccatgaa cagaaatccc cc t tacacgg aggcatcagt  
1 5 0 0  
1 5 6 0  
1 6 2 0  
1 6 8 0  
1 7 4 0  
1 8 0 0  
1 8 6 0  
1 9 2 0  
1 9 8 0  
2 0 4 0  
2 1 0 0  
2 1 6 0  
2 2 2 0  
2 2 8 0  
2 3 4 0  
2 4 0 0  
2 4 6 0  
2 5 2 0  
2 5 8 0  
2 6 4 0  
2 7 0 0  
2 7 6 0  
2 8 2 0  
2 8 8 0  
2 9 4 0  
3 0 0 0  
3 0 6 0  
3 1 2 0  
3 1 8 0  
3 2 4 0  
3 3 0 0  
3 3 6 0  
3 4 2 0  
3 4 8 0  
3 5 4 0  
3 6 0 0  
3 6 6 0  
3 7 2 0  
3 7 8 0  
3 8 4 0  
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gaccaaacag gaaaaaaccg c c c t t a a c a t  g g c c c g c t t t  atcagaagcc agacat taac 
g c t t c t g g a g  aaactcaacg agctggacgc ggatgaacag gcagacatc t  g t g a a t c g c t  
tcacgaccac gctgatgagc t t t a c c g c a g  c tgcc tcgcg c g t t t c g g t g  atgacggtga 
aaacctc tga cacatgcagc tcccggagac ggtcacagct  t g t c t g t a a g  cggatgccgg 
gagcagacaa gcccgtcagg gcgcgtcagc gggtg t tggc  gggtgtcggg gcgcagccat 
gacccagtca cgtagcgata gcggagtgta t a c t g g c t t a  actatgcggc atcagagcag 
a t t g t a c t g a  gagtgcacca t a t a t g c g g t  gtgaaatacc gcacagatgc gtaaggagaa 
aataccgcat  caggcgctc t  t c c g c t t c c t  cgc tcac tga  c tcgc tgcgc  t c g g t c g t t c  
ggctgcggcg agcggtatca gctcactcaa aggcggtaat a c g g t t a t c c  acagaatcag 
gggataacgc aggaaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa 
aggccgcgt t  g c t g g c g t t t  t t c c a t a g g c  tccgcccccc tgacgagcat  cacaaaaatc 
gacgctcaag tcagaggtgg cgaaacccga caggactata aagataccag g c g t t t c c c c  
c tggaagctc  cctcgtgcgc t c t c c t g t t c  cgaccctgcc gct taccgga t a c c t g t c c g  
c c t t t c t c c c  ttcgggaagc g t g g c g c t t t  c t c a t a g c t c  acgctgtagg t a t c t c a g t t  
cgg tg taggt  c g t t c g c t c c  aagctgggct  g tgtgcacga accccccgt t  cagcccgacc 
g c t g c g c c t t  a tccggtaac t a t c g t c t t g  agtccaaccc ggtaagacac g a c t t a t c g c  
cactggcagc agccactggt  aacaggatta gcagagcgag g ta tg taggc  ggtgctacag 
a g t t c t t g a a  g tgg tggcc t  aactacggct  acactagaag g a c a g t a t t t  g g t a t c t g c g  
c t c t g c t g a a  gccagt tacc t tcggaaaaa gagt tgg tag  c t c t t g a t c c  ggcaaacaaa 
ccaccgctgg tagcggtgg t  t t t t t t g t t t  gcaagcagca gat tacgcgc agaaaaaaag 
gatc tcaaga a g a t c c t t t g  a t c t t t t c t a  cggggtctga cgc tcagtgg  aacgaaaact 
cacgt taagg g a t t t t g g t c  atgaacaata a a a c t g t c t g  c t t a c a t a a a  cagtaataca 
aggggtg t ta  tgagccata t  tcaacgggaa a c g t c t t g c t  ctaggccgcg a t t a a a t t c c  
aacatggatg c t g a t t t a t a  tgggta taaa tgggctcgcg a t a a t g t c g g  gcaatcaggt  
gcgacaatct  a t c g a t t g t a  tgggaagccc gatgcgccag a g t t g t t t c t  gaaacatggc 
aaaggtagcg t t g c c a a t g a  t g t t a c a g a t  gagatggtca gactaaactg gctgacggaa 
t t t a t g c c t c  t t c c g a c c a t  c a a g c a t t t t  a t c c g t a c t c  c tga tga tgc  a t g g t t a c t c  
accactgcga tccccgggaa aacagcat tc  caggta t tag  aagaatatcc t g a t t c a g g t  
gaaaata t tg  t t g a t g c g c t  ggcagtg t tc  c tgcgccggt  t g c a t t c g a t  t c c t g t t t g t  
a a t t g t c c t t  t taacagcga t c g c g t a t t t  c g t c t c g c t c  aggcgcaatc acgaatgaat 
aacggt t tgg  t tga tgcgag t g a t t t t g a t  gacgagcgta atggctggcc t g t t g a a c a a  
gtc tggaaag aaatgcataa a c t t t t g c c a  t t c t c a c c g g  a t t c a g t c g t  c a c t c a t g g t  
g a t t t c t c a c  t t g a t a a c c t  t a t t t t t g a c  gaggggaaat t a a t a g g t t g  t a t t g a t g t t  
ggacgagtcg gaatcgcaga ccgataccag g a t c t t g c c a  t c c t a t g g a a  c t g c c t c g g t  
g a g t t t t c t c  c t t c a t t a c a  gaaacggct t  t t t c a a a a a t  a t g g t a t t g a  t a a t c c t g a t  
a tgaataaat  t g c a g t t t c a  t t t g a t g c t c  g a t g a g t t t t  t c t a a g a a t t  a a t t c a t g a g  
cggatacata t t t g a a t g t a  t t tagaaaaa taaacaaata ggggt tccgc g c a c a t t t c c  
ccgaaaagtg ccacctgaaa t t g t a a a c g t  t a a t a t t t t g  t t a a a a t t c g  c g t t a a a t t t  
t t g t t a a a t c  a g c t c a t t t t  t t a a c c a a t a  ggccgaaatc ggcaaaatcc c t t a t a a a t c  
3 9 0 0  
3 9 6 0  
4 0 2 0  
4 0 8 0  
4 1 4 0  
4 2 0 0  
4 2 6 0  
4 3 2 0  
4 3 8 0  
4 4 4 0  
4 5 0 0  
4 5 6 0  
4 6 2 0  
4 6 8 0  
4 7 4 0  
4 8 0 0  
4 8 6 0  
4 9 2 0  
4 9 8 0  
5 0 4 0  
5 1 0 0  
5 1 6 0  
5 2 2 0  
5 2 8 0  
5 3 4 0  
5 4 0 0  
5 4 6 0  
5 5 2 0  
5 5 8 0  
5 6 4 0  
5 7 0 0  
5 7 6 0  
5 8 2 0  
5 8 8 0  
5 9 4 0  
6 0 0 0  
6 0 6 0  
6 1 2 0  
6 1 8 0  
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aaaagaatag accgagatag g g t t g a g t g t  t g t t c c a g t t  tggaacaaga g t c c a c t a t t  6 2 4 0  
aaagaacgtg gactccaacg tcaaagggcg aaaaaccgtc ta tcagggcg a tggcccac t  6 3 0 0  
acgtgaacca t caccc taa t  c a a g t t t t t t  ggggtcgagg tgccgtaaag  cac taaa tcg  6 3 6 0  
gaaccctaaa gggagccccc g a t t t a g a g c  t tgacgggga  aagccggcga acgtggcgag 6 4 2 0  
aaaggaaggg aagaaagcga aaggagcggg cgctagggcg c tggcaagtg  tagcggtcac  6 4 8 0  
gctgcgcgta  accaccacac ccgccgcgct taa tgcgccg  ctacagggcg c g t c c c a t t c  6 5 4 0  
gcca 6 5 4 4  
<210>  SEQ I D  NO 4 1  
<211>  LENGTH: 426  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: designed p r o t e i n  
<400>  SEQUENCE: 4 1  
M e t  G l y  I l e  G l u  G l u  G l y  L y s  L e u  V a l  I l e  T r p  I l e  A s n  G l y  A s p  L y s  
1 5 1 0  1 5  
G l y  T y r  A s n  G l y  L e u  A l a  G l u  V a l  G l y  L y s  L y s  Phe G l u  L y s  A s p  T h r  
20  2 5  3 0  
G l y  I l e  L y s  V a l  T h r  V a l  G l u  H i s  P r o  A s p  L y s  L e u  G l u  G l u  L y s  Phe 
35  40 45 
P r o  G l n  V a l  A l a  A l a  T h r  G l y  A s p  G l y  P r o  A s p  I l e  I l e  Phe T r p  A l a  
5 0  5 5  6 0  
H i s  A s p  A r g  Phe G l y  G l y  T y r  A l a  G l n  S e r  G l y  L e u  L e u  A l a  G l u  I l e  
6 5  7 0  7 5  8 0  
T h r  P r o  A s p  L y s  A l a  Phe G l n  A s p  L y s  L e u  T y r  P r o  Phe T h r  T r p  A s p  
8 5  9 0  95  
A l a  V a l  A r g  T y r  A s n  G l y  L y s  L e u  I l e  A l a  T y r  P r o  I l e  A l a  V a l  G l u  
1 0 0  1 0 5  1 1 0  
A l a  L e u  S e r  L e u  I l e  T y r  A s n  L y s  A s p  L e u  L e u  P r o  A s n  P r o  P r o  L y s  
1 1 5  1 2 0  1 2 5  
T h r  T r p  G l u  G l u  I l e  P r o  A l a  L e u  A s p  L y s  G l u  L e u  L y s  A l a  L y s  G l y  
1 3 0  1 3 5  1 4 0  
L y s  S e r  A l a  L e u  M e t  Phe A s n  L e u  G l n  G l u  P ro  T y r  Phe T h r  T r p  P r o  
1 4 5  1 5 0  1 5 5  1 6 0  
L e u  I l e  A l a  A l a  A s p  G l y  G l y  T y r  A l a  Phe L y s  T y r  G l u  A s n  G l y  L y s  
1 6 5  1 7 0  1 7 5  
T y r  A s p  I l e  L y s  A s p  V a l  G l y  V a l  A s p  A s n  A l a  G l y  A l a  L y s  A l a  G l y  
1 8 0  1 8 5  1 9 0  
L e u  T h r  Phe L e u  V a l  A s p  L e u  I l e  L y s  A s n  L y s  H i s  M e t  A s n  A l a  A s p  
1 9 5  2 0 0  2 0 5  
T h r  A s p  T y r  S e r  I l e  A l a  G l u  A l a  A l a  Phe A s n  L y s  G l y  G l u  T h r  A l a  
2 1 0  2 1 5  2 2 0  
M e t  T h r  I l e  A s n  G l y  P r o  T r p  A l a  T r p  S e r  A s n  I l e  A s p  T h r  S e r  L y s  
2 2 5  2 3 0  2 3 5  2 4 0  
V a l  A s n  T y r  G l y  V a l  T h r  V a l  L e u  P r o  T h r  Phe L y s  G l y  G l n  P r o  S e r  
2 4 5  2 5 0  2 5 5  
L y s  P r o  Phe V a l  G l y  V a l  L e u  S e r  A l a  G l y  I l e  A s n  A l a  A l a  S e r  P r o  
2 6 0  2 6 5  2 7 0  
A s n  L y s  G l u  L e u  A l a  L y s  G l u  Phe L e u  G l u  A s n  T y r  L e u  L e u  T h r  A s p  
2 7 5  2 8 0  2 8 5  
G l u  G l y  L e u  G l u  A l a  V a l  A s n  L y s  A s p  L y s  P ro  L e u  G l y  A l a  V a l  A l a  
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2 9 0  2 9 5  3 0 0  
L e u  L y s  S e r  T y r  G l u  G l u  G l u  L e u  A l a  L y s  A s p  P r o  A r g  I l e  A l a  A l a  
3 0 5  3 1 0  3 1 5  3 2 0  
T h r  M e t  G l u  A s n  A l a  G l n  L y s  G l y  G l u  I l e  M e t  P r o  A s n  I l e  P r o  G l n  
3 2 5  3 3 0  3 3 5  
M e t  S e r  A l a  Phe T r p  T y r  A l a  V a l  A r g  T h r  A l a  V a l  I l e  A s n  A l a  A l a  
3 4 0  3 4 5  3 5 0  
S e r  G l y  A r g  G l n  T h r  V a l  A s p  G l u  A l a  L e u  L y s  A s p  A l a  G l n  T h r  A s n  
3 5 5  3 6 0  3 6 5  
S e r  S e r  S e r  G l y  G l y  S e r  G l y  S e r  G l y  M e t  A s p  G l u  L y s  T h r  T h r  G l y  
3 7 0  3 7 5  3 8 0  
T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  L e u  A l a  G l y  G l u  L e u  G l u  G l n  
3 8 5  3 9 0  3 9 5  400  
L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  G l n  G l y  G l n  A r g  G l u  P r o  G l y  
4 0 5  410  4 1 5  
S e r  G l y  H i s  H i s  H i s  H i s  H i s  H i s  G l u  Phe 
420  4 2 5  
2s 
What is claimed is: sequence having at least 80% identity to the first 38 
1. A peptide which binds streptavidin with a dissociation amino acids of SEQ ID NO:25, wherein said peptide 
constant less than 10 pM and comprises an amino acid does not contain an HPQ, HPM, HPN, or HQP motif; 
sequence having at least 80% identity to the first 38 amino or 
constant less than 23 nM and comprises an amino acid bonded or cyclized. 2. A peptide which binds streptavidin with a dissociation sequence having at least 80% identity to the first 38 constant less than 10 pM and comprises an amino acid amino acids of SEQ ID NO:25. sequence having at least 80% identity to the first 38 amino 
acids of SEQ ID NO:25, wherein the amino acid sequence 3s 11. The fusion protein of claim 10, wherein said peptide 
of said peptide does not contain an HpQ, HpM, HpN, or is attached to the amino terminus or the carboxy terminus of 
HQP motif. said protein of interest, or wherein said peptide is positioned 
3, A peptide which binds streptavidin with a dissociation between the amino and carboxy termini of said protein of 
constant less than 23 nM and comprises an amino acid interest. 
sequence having at least 80% identity to the first 38 amino 40 12. The fusion Protein of claim 10, wherein said Peptide 
acids of SEQ ID NO:25. is linked to said protein of interest by a linker comprising a 
4. The peptide of claim 1 or 2, wherein said dissociation protease-sensitive site. 
constant is less than 5 pM. 13. The peptide of claim 1, wherein said peptide com- 
5. The peptide of claim 1 or 2, wherein said dissociation prises at least the first 38 amino acids of SEQ ID NO:25. 
constant is less than 1 pM. 14. The peptide of claim 1, wherein said peptide has at 
6. The peptide of claim 5,  wherein said dissociation least 90% sequence identity to SEQ ID ~ 0 ~ 2 5 .  
constant is less than 100 nM. 15. The peptide of claim 1, wherein said peptide has at 
7. The peptide of claim 6, wherein said dissociation least 95% sequence identity to SEQ ID ~ 0 ~ 2 5 ,  
constant is less than 50 nM. 16. The peptide of claim 2, wherein said peptide has at 
8. The peptide of claim 3, wherein said dissociation 50 least 90% sequence identity to SEQ ID NO:25, 
17. The peptide of claim 2, wherein said peptide has at constant is less than 10 nM. 
9. The peptide of claim 8, wherein said dissociation least 95% sequence identity to SEQ ID NO:25, 
18. The peptide of claim 3, wherein said peptide has at constant is less than 5 nM. 
10. A fusion protein comprising a protein of interest least 90% sequence identity to SEQ ID NO:25, 
19. The peptide of claim 3, wherein said peptide has at covalently linked to: 
(a) a peptide which binds streptavidin with a dissociation least 95% sequence identity to SEQ ID ~ 0 ~ 2 5 ,  
constant less than 10 PM and comprises an amino acid 20. The peptide of claim 10, wherein said peptide has at 
sequence having at least 80% identity to the first 38 least 90% sequence identity to SEQ ID ~ 0 ~ 2 5 ,  
amino acids of SEQ ID NO:25, wherein said peptide is 21. The peptide of claim 10, wherein said peptide has at 
not disulfide bonded or cyclized; least 95% sequence identity to SEQ ID NO:25. 
(b) a peptide which binds streptavidin with a dissociation 
acids Of SEQ ID NO125, wherein said peptide is not disulfide 30 a peptide which binds streptavidin with a dissociation 
45 
5s 
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constant less than 10 pM and comprises an amino acid * * * * *  
